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One-sentence summary: RSK4 promotes invasiveness and drug resistance in lung and bladder 
cancer and inhibition of this kinase shows therapeutic potential. 
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Abstract 
Lung and bladder cancers are mostly incurable due to early development of drug resistance and 
metastatic dissemination. Hence, better therapies that tackle these two processes are urgently 
needed to improve clinical outcome. We have identified RSK4 as a promoter of drug resistance and 
metastasis in lung and bladder cancer cells. Silencing this kinase, either through RNA interference or 
CRISPR, sensitised tumor cells to chemotherapy and hindered metastasis in vitro and in vivo in a tail-
vein injection model. Drug screening revealed several floxacin antibiotics as potent RSK4 activation 
inhibitors and trovafloxacin reproduced all effects of RSK4 silencing in vitro and in/ex vivo using lung 
cancer xenograft and genetically-engineered mouse models and bladder tumour explants. Through 
X-ray structure determination and Markov transient and Deuterium exchange analyses, we 
identified the allosteric binding site and revealed how this compound blocks RSK4 kinase activation 
through binding to an allosteric site and mimicking a kinase auto-inhibitory mechanism involving the 
RSK4’s hydrophobic motif. Last, we show that patients undergoing chemotherapy and adhering to 
prophylactic levofloxacin in the large placebo-controlled randomised phase 3 SIGNIFICANT Trial had 
significantly (p =0.048) increased long-term overall survival times. Hence, we suggest that RSK4 




Lung and bladder cancers are two smoking-related malignancies that are mostly incurable due to the 
early development of drug-resistant metastatic disease. Hence, a better understanding of the 
molecular mechanisms regulating these processes will help develop therapeutic strategies against 
these malignancies. 
The p90 Ribosomal Protein S6 kinases (RPS6KAs, aka RSKs) are dual kinase domain protein kinases 
involved in multiple processes including protein translation, cell growth, and migration (1). Four 
isoforms exist in humans (RSK1-4) of which RSK1 and 2 are most studied in cancer. Their biological 
functions are assumed to overlap with RSK3 and 4 because these proteins have a high degree of 
sequence identity, especially in their N-terminal kinase domain that mediates substrate 
phosphorylation. However, our previous work challenged this notion. Indeed, RSK1 differed from 
other isoforms in its regulation of lung cancer cell invasion as silencing of this kinase promoted 
metastasis in vitro (8). This suggested that the use of pan-RSK inhibitors may not be optimal for anti-
cancer treatments (2). Moreover, RSK4 differs from other RSKs in its activation mechanism, with this 
isoform only requiring ERK whereas RSK1-3 need both ERK and PDK1 (1). Therefore, we hypothesise 
that RSK4 has divergent functions and activation patterns from other RSK isoforms. 
The role of RSK4 in cancers is controversial due to conflicting experimental data. A tumour 
suppressor function of RSK4 was suggested in MDA-231 breast cancer cells where RSK4 
overexpression leads to cell cycle arrest, reduced clonogenic growth in vitro, and reduced tumour 
growth and dissemination in vivo (3). In colon carcinoma cell lines, RSK4 overexpression triggered 
senescence (4) consistent with large RNAi screens where RSK4 downregulation prevented p53-
induced senescence (5). In addition, in breast, colon and renal carcinoma, RSK4 mRNA expression 
was downregulated in tumour compared to normal tissues (1) . In contrast, several studies in the 
same or different cancers suggest a tumour-promoting function for RSK4. Thus, over-expression of 
RSK4 enhanced whereas knockdown impaired cell migration and sunitinib resistance in renal and 
melanoma cell lines (6). Furthermore, RSK4 is over-expressed in breast and renal cancer at either the 
protein or mRNA levels (1) and in renal cancers this associated with poor patient prognosis (7). 
Moreover, RSK4 overexpression promoted, and silencing reduced, invasiveness of renal cell 
adenocarcinoma cells in vitro. One plausible explanation for these conflicting data is that RSK4 may 
act as a tumour suppressor or promoter in a context- or disease-dependent manner.Apart from our 
study demonstrating that RSK4 knockdown prevented migration and invasion of lung 
adenocarcinoma cells (8), the role of this kinase in lung and bladder cancer has not previously been 
investigated. 
Here, we investigate the role of RSK4 in mediating lung and bladder cancer cell invasion as well as 
sensitization to chemotherapy both in vitro and in vivo through genetic manipulation (silencing and 
overexpression) and identify potential mechanisms to explain the effects seen. We also, screen 
known drugs to identify drugs or drug families which could be re-purposed as RSK4 inhibitors and 
crystalise part of RSK4 and undertake Markov transient and deuterium exchange analyses to assess 
their mechanism of action. We further test whether one of these drugs reproduces our genetic 
silencing data in vitro and in vivo and search for cancer patient trials that have previously used 
members of the drug family of interest. One such trial is found and re-analysed for whether the re-
purposed drug in combination with chemotherapy could prolong survival of lung and bladder plus 




siRNA screening reveals RSK4 as a regulator of chemosensitivity in lung and bladder cancer cells 
 
To identify common regulators of chemo response in lung and bladder cancer, we performed a 
kinome siRNA screen in T24 bladder cancer cells treated with or without taxol or cisplatin and 
compared this to our prior screen in lung cancer cells (9). Four individual siRNA sequences targeting 
each kinase were used and hits selected for validation based on at least 2 sequences similarly 
modulating drug sensitivity (fig S1A-C). Amongst kinases found to control drug sensitivity (Fig 1A), 23 
regulated the response to both cisplatin and taxol (Fig 1B, fig. S1C), and 13 of these were cross-
validated in 2 additional bladder cancer cell lines, TCCSUP and J82 (Fig 1C, fig. S1D). Cross-correlating 
these results with those previously-published for A549 lung adenocarcinoma cells (9) revealed RSK4 
(aka RPS6KA6) as a potential common target between lung and bladder cancer. Indeed, we 
confirmed that silencing RSK4 sensitised both bladder and lung cancer cells to taxol and cisplatin (Fig 
1D). This was reproduced in additional lung cancer cell lines (fig S2A) independently from the 
modality of RSK4 downregulation as two A549 clones in which RSK4 was knocked-out using CRISPR 
technology showed similar drug sensitisation (Fig 1E). This was associated with potentiation of 
apoptosis and increased DNA damage as assessed by caspase 3/7 activation (Fig 1F) and elevated 
phospho-H2AX nuclear foci (Fig 1G), respectively. However, RSK4-silenced cells did not show 
decreased cell viability in the absence of drug (Fig 1D), despite increased total caspase 7 expression, 
as well as cleavage of caspase 7 and PARP (Fig 1H, fig. S2B), suggesting that RSK4-knockdown only 
primes the apoptotic process. Conversely, RSK4 overexpression made A549 cells chemoresistant (fig 
S2C), with decreased background caspase activation and PARP cleavage (fig S2D). The increased 
caspase 3/7 activity in RSK4-downregulated cells was rescued by RSK4 overexpression (fig S2E).  In 
multiple NSCLC and T24 cell lines, sensitisation to chemotherapy was associated with decreased 
expression of the anti-apoptotic proteins BCL2, cIAP1 and cIAP2 that we previously showed promote 
chemo-resistance in lung cancer (Fig 1I, fig. S2F) (10). This decrease occurred at the transcriptional 
level (Fig 1J). Similar decreases in cIAP1 and cIAP2, but not BCL2, occurred in A549 RSK4-CRISPR 
clones (fig S2G), which may indicate that cIAP changes are more relevant to chemosensitisation in 
this biological context. Moreover, cIAP2 is likely the major mediator of the RSK4-induced 
chemoresistance as only cIAP2 mRNA and protein expression were increased by RSK4 
overexpression in A549 cells (fig S2H-I) and cIAP2 but not cIAP1 rescued chemosensitisation 
following RSK4 silencing (fig S2J). In short, RSK4 downregulation promotes cell death in several lung 
and bladder cancer cell lines treated with two clinically relevant chemotherapeutic compounds. 
 
RSK4 controls the migration and invasion of lung and bladder cancer cells 
 
We previously published that RSK4 silencing decreased the migration and invasion of A549 cells (8). 
Similarly, RSK4 knockdown hindered the migration and invasion of bladder and lung cancer cell lines 
(Fig 2A, 2B, fig. S3A), whereas RSK4 overexpression promoted migration of A549 cells (fig S3B). 
Microscopic image analysis of RSK4-silenced cells revealed increased cell clustering and roundness 
(Fig. 2C, fig. S3C), suggesting a reversal of epithelial-mesenchymal transition (EMT). In agreement, 
analysis of lysates from RSK4-silenced and control cells for EMT markers revealed decreased 
vimentin and N-cadherin and increased epithelial marker E-cadherin (Fig. 2D-left, fig. S3D-E). 
Conversely, RSK4 overexpression had the opposite effect (Fig. 2D-right, fig. S3F). The decreased cell 
migration observed after siRNA-mediated RSK4 silencing was reproduced in RSK4-CRISPR A549 cells 
and rescued by RSK4 overexpression, demonstrating the RSK4-selectivity of this phenotype (fig. 
S3G). EMT is partly controlled by NFκB (11) and reduced expression of EMT markers after RSK4 
downregulation associated with decreased NFκB activity (Fig. 2E, fig. S3H) and decreased RELA 
nuclear localisation (Fig. 2F). This suggested that NFκB activity is controlled by RSK4. RELA nuclear 
accumulation is negatively regulated through acetylation on K122 and K123 by the acetyl-transferase 
p300 (12). Figure 2G shows that Ser89 phosphorylation of p300, an event that inhibits p300’s acetyl-
transferase activity (13), was decreased in RSK4-silenced A549 and T24 cells. Consequently, RSK4 
may regulate the activity of the NFκB pathway by direct phosphorylation of p300, as recombinant 
RSK4 phosphorylates p300 on Ser89 in vitro (Fig. 2H). The role of NFkB in RSK4’s effects on EMT 
markers and cell migration were confirmed by active-RELA overexpression reverting the changes in 
EMT markers and decreased cell migration in RSK4-downregulated A549 cells (fig. S4A-B). In 
contrast, RSK4-induced chemo-resistance was not mediated by RELA, as active-RELA overexpression 
failed to prevent drug sensitisation or decreased cIAP2 expression in RSK4-downregulated cells (fig. 
S4C-E). Although changes in cell migration and the actin cytoskeleton play important roles in cellular 
invasion, resistance to anoikis is crucial to metastatic dissemination, as this maximises the survival of 
circulating cancer cells (14). Figure 2I shows that unlike RSK1-silenced or non-targeted cells, RSK4-
downregulated A549 and T24 cells underwent cell death when placed in suspension for 18h. Taken 
together, our data suggest that RSK4 silencing impairs the metastatic program of lung and bladder 
cancer cells. 
 
RSK4 is overexpressed in lung cancer and correlates with decreased survival in patients with 
adenocarcinoma 
 
To assess the potential clinical relevance of our findings, we analysed tissue microarrays of normal 
and lung cancer tissue samples for RSK4 protein expression. Staining optimisation using paraffin-
embedded A549 cells silenced or not for RSK4 demonstrated that immunoreactivity depended on 
RSK4 expression, therefore confirming the antibody’s specificity (fig. S5A), similarly to that observed 
in Western blotting (fig. S5B). Figure 3A shows that whereas RSK4 was undetectable in all normal 
lung specimens, 57% of primary lung cancers (n=97) were positive for this kinase. Western blotting 
of NSCLC and normal lung epithelial cell lines showed similar differences, suggesting that RSK4 
expression in our cell lines was representative of that seen in the clinic (fig. S5C). Stratifying our 
clinical samples for lung cancer subtypes showed that the frequency and intensity of RSK4 
expression was highest in adenocarcinoma (AdCa), decreased in squamous cell (SCC) NSCLC and 
lowest in small cell lung cancers (SCLC) (Fig. 3B-C). Similar differences were observed at mRNA level 
in TCGA datasets where lung AdCa, but not SCCs showed a significant (p=3.27e-06) increase in RSK4 
expression over normal lung (Fig. 3D). To test whether RSK4 was important in lung AdCa, we 
analysed publically available lung cancer survival data. When all lung cancer subtypes were 
considered, high RSK4 mRNA expression associated with poorer prognosis (fig. S5D). However, when 
subtypes were separated, high-expressing AdCa showed significant decreased overall survival (OS) 
(p= 9.6 10-6) whereas survival of patients with SCC was unaffected (Fig. 3E). This association between 
RSK4 expression and OS existed despite RSK4 expression being far lower than other RSK isoforms 
across all lung cancers or AdCa alone (fig. S5E). Amongst other RSKs, only RSK3 showed increased 
mRNA expression in AdCa compared to normal lung samples, whereas RSK2 showed decreased and 
RSK1 unchanged expression (fig. S5F). Nevertheless, a negative association between RSK expression 
and survival was only observed for RSK4 as similar analysis for other RSK isoforms showed that high 
expression either did not impact (RSK1) or was associated with improved OS (RSK2 and RSK3) in 
patients with AdCa (fig. S5G). Similar to the case of lung AdCa, analysis of bladder cancer samples 
showed lower RSK4 mRNA expression as compared to other RSKs (fig. S6A), and RSK4 overexpresion 
in cancer as compared to normal bladder samples (fig. S6B).  Last, consistent with our in vitro data 
showing that RSK4 mediates the invasiveness of lung AdCa cells, we found that 52% of AdCa 
metastatic lesions expressed more RSK4 protein than their corresponding primary tumours, whereas 
this number fell to 24% in SCC (Fig. 3F). These results are also consistent with the difference in 
correlation between OS and RSK4 expression in patients with lung AdCa and SCC. Taken together, 
our data suggest that RSK4 over-expression as a predictor of survival might be most relevant in lung 
AdCa.  
 
RSK4 silencing impairs tumour progression and maximises therapy response in vivo 
 
We next assessed the effects of RSK4 silencing on tumour growth in vivo using A549 non-targeting or 
RSK4-CRISPR cells injected subcutaneously into nude mice. Tumour growth was noticeably delayed 
for both RSK4-CRISPR clones tested as compared to their non-targeted counterpart (Fig. 4A). 
Moreover, potentiation of cisplatin response was seen for RSK4-CRISPR as compared to non-
targeted tumours (Fig. 4A-B). Because RSK4 silencing imparied cell invasion and anoikis in vitro, we 
also assessed metastasis in vivo. RSK4-CRISPR or non-targeted A549 cells were injected into the tail 
vein of Severe Combined Immunodeficiency (SCID) mice and their lungs histologically examined 2 
months later. This revealed a decreased ability of RSK4-CRISPR cells to colonise the lungs of injected 
mice (Fig 4C, fig. S7). Hence, RSK4 downregulation hinders lung adenocarcinoma tumour growth and 
dissemination in vivo. 
 
Small compound library screening identifies moxifloxacin as a RSK4 activation inhibitor 
 
Our data suggested that RSK4 inhibition may be clinically beneficial in the treatment of lung 
adenocarcinoma. Although pan-RSK inhibitors exist (15) (16), we previously published that RSK1 
downregulation promotes lung cancer invasiveness (8). Here, we reproduce this finding by treating 
A549 cells with the pan-RSK inhibitor SL-0101 (fig. S8A). Moreover, contrary to the results obtained 
for RSK4, RSK1 silencing in bladder and lung cancer cells induced resistance to taxol and cisplatin (fig. 
S8B) and increased cIAP2 expression (fig. S8C). Last, unlike RSK4, RSK1 was well expressed in normal 
lung epithelial cells as aforementioned. Hence, inhibiting this kinase as part of therapeutic targeting 
of RSK4 may yield distinct toxicity and loss of anti-cancer effects. Consequently, we wished to 
identify selective RSK4 inhibitors. We therefore developed a high-throughput Homogeneous Time-
Resolved Fluorescence (HTRF)-based assay to identify molecules interfering with RSK4 activation by 
ERK as, unlike other RSKs, RSK4 does not require PDK1 (1). Because bacterially-produced 
recombinant RSK4 showed high basal activity in vitro, we first inactivated it through 
dephosphorylation with the phosphatase PP1MA before incubation with test compounds and 
subsequent re-activation by ERK2 (Fig. 5A, fig. S8D). This favoured the selection of molecules likely 
to be non-ATP competitive. We screened 1675 molecules and discovered twelve compounds 
showing >75% inhibition of RSK4 activation at 30 µM, amongst which was the antibiotic, 
moxifloxacin (Fig. 5B). This molecule acted as a micromolar (IC50=6.2 µM) non-ATP competitive 
reversible inhibitor of RSK4 activation (fig. S8E-F) and did not interfere with ERK activity in contrast 
to the well documented ATP-competitive pan-RSK inhibitor, BI-D1870 (fig. S8G). Increasing the 
concentration of RSK4 by 10 fold did not modify the efficiency of moxifloxacin, suggesting it does not 
act by degrading RSK4 (fig. S8E). Time-dependence inhibition studies showed a linear relationship 
with product formation in the presence of moxifloxacin or BI- D1870 (fig. S8H), indicating that 
moxifloxacin is not a slow binder and that mechanism of action studies could be performed using 
classical steady-state analysis. Michaelis Menten kinetics confirmed that in the presence of sub-
maximal inhibition by BI-D1870, RSK4 maintained ATP Vmax but showed a trend to increased Km in 
agreement with the ATP competitive nature of this inhibitor (fig. S8J-K). In contrast, when incubated 
with moxifloxacin, RSK4 maintained Km and displayed reduced Vmax (α = 1), confirming ATP non-
competitive binding equally to the Enzyme and Enzyme-Substrate state of the enzyme (fig. S8I-K). 
Moreover, Moxifloxacin showed a preference for preventing RSK4 activation rather than inhibiting 
fully-active RSK4 and further favoured RSK4 over RSK1 (fig. S8L), making this compound a useful 
chemical starting point for future synthesis of RSK4-selective inhibitors. 
 
Trovafloxacin reproduces the effects of RSK4 silencing in vitro 
 
Following our results with moxifloxacin, we screened other floxacin family members in our RSK4 
HTRF-activation assay and identified both additional inhibitors (trovafloxacin, marbofloxacin, 
rufloxacin, tosufloxacin) as well as inactive analogues (ciprofloxacin, danofloxacin, and piromidic 
acid) (Fig. 5B, fig. S9A). As all these compounds are active antibiotics, we assumed that their RSK4-
targeting activity was independent of their known clinical indication. However, no clear structure-
activity relationship was readily identifiable (fig. S10). Crucially, only the compounds active against 
RSK4 sensitised A549 cells to cisplatin (Fig. 5C, fig. S11A). In particular, trovafloxacin showed 
superior abilities to moxifloxacin in this assay with 7.5 µM of this compound reducing the IC50 for 
cisplatin (Fig. 5C). This relationship was synergistic (fig. S11B) and the potentiation of cisplatin or 
taxol effects maximal when combined with ≈10 µM trovafloxacin (fig. S11B-C). This correlated with 
promotion of caspase activation in response to drug treatment in A549 cells (Fig. 5D), an effect 
dependent on the expression of RSK4. Indeed, RSK4 silencing using a 5’UTR-targeting siRNA 
prevented potentiation of caspase activation by trovafloxacin over that obtained with cisplatin alone 
whereas simultaneous RSK4 overexpression rescued this difference (Fig. 5E). In contrast, the pan-
RSK inhibitor BI-D1870 failed to promote cisplatin-induced caspase activation (Fig. 5E). As with RSK4 
silencing, increased apoptosis in response to trovafloxacin associated with decreased expression of 
BCL2 and cIAP1/2, an effect not seen with either ciprofloxacin (non-RSK4 inhibitor) or BI-D1870 (Fig 
5F, fig. S11D). Moreover, trovafloxacin treatment reproduced the inhibition of cell 
migration/invasiveness (Fig. 5G-H, fig. S11E-F) and EMT reversal (fig. S11G) previously observed with 
RSK4 silencing in A549 cells. Other RSK4-targeting floxacins (moxifloxacin, tosufloxacin) shared this 
ability, whereas non RSK4-targeting compounds (ciprofloxacin, danofloxacin) did not impair cell 
invasiveness (Fig. 5H). In addition, differential scanning fluorimetry assays demonstrated that 
trovafloxacin bound the inactive/dephosphorylated, but not the fully-active, RSK4 N-terminal kinase 
domain (RSK4-NTKD) (Fig. 5I), supporting the selectivity profile previously seen for moxifloxacin. In 
contrast, ciprofloxacin failed to bind RSK4 in the same assay (fig. S11H), explaining why this 
compound fails to inhibit this kinase. Last, we tested 10 µM trovafloxacin, corresponding to the IC50 
of this drug on recombinant RSK4, against a panel of 140 kinases in an in-vitro activity screen. No 
other kinase was substantially inhibited by trovafloxacin at this concentration (Supplementary Excel 
data file). In short, trovafloxacin appears to be a reasonably-selective allosteric RSK4-NTKD 
activation inhibitor. 
 
RSK4-NTKD crystal structures  
 
To obtain structural and mechanistic information on RSK4 and elucidate how it might be 
allosterically regulated, we solved the crystal structures of the phosphorylated (pS232) and 
dephosphorylated RSK4-NTKD, as well as the S232E phospho-mimetic mutant (table S1, fig. S12A-C). 
All three structures display a classic bilobal protein kinase fold (Fig. 6A), with the activation loop, 
which runs between the C- and N-lobes, well-ordered and visible in dephosphorylated and pS232 
RSK4-NTKD structures. The overall folding of these NTKD versions is identical, with an RMSD of 0.35 
Å between RSK4 NTKD chain A and RSK4 NTKD S232E chain A, and 0.33 Å between RSK4 NTKD chain 
A and RSK4 NTKD pS232 chain A.The two molecules in the asymmetric unit of the RSK4 NTKD pS232 
are in the same orientation seen for the dephosphorylated protein, with only 2.6 Å translation of 
chain B in respect to its relative position in RSK4 NTKD when using chain A as reference. During the 
refinement stage of RSK4 NTKD pS232, we found a well-defined electron density on the activation 
loop of chain A in which it was possible to model the phosphate of phosphorylated S232 (fig. S12A). 
The phosphorylation is oriented inward and points towards D197, part of the HRD motif, and, at the 
same time, the side chain of D197 moves ~1.3 Å closer to the activation loop compared to its relative 
position on the dephosphorylated structure. 
In all three structures the top part of the C-helix, present in classical protein kinase topology (17), is 
disordered with the bottom part forming a helix that swings away from its classical position in PKA 
by up to 12 Å (Fig. 6B). In this new position, the C-helix is not involved in any catalytic activities. In its 
place lies the βB-sheet formed by β1-β5-β10 (residues: 52-56, 109-115, 220-222). The βB-sheet has 
been previously seen in both MSK1- and RSK2-NTKD crystal structures (18, 19), suggesting that this 
motif may characterise AGC family members with two kinase domains on the same polypeptide 
chain. Furthermore, in agreement with the RSK2-NTKD structure (18), our data suggest that the βB-
sheet is a structural feature of both inactive and active states. This was confirmed by far UV CD 
spectra of the three proteins, which are characteristic of a mixed αβ secondary structure content 
and suggest the absence of major conformational changes between inactive and active states (fig. 
S12A, fig. S12D). This absence may facilitate RSK4 activation, as it would lower the energy barrier to 
reach the active state and is consistent with the high autophosphorylation property of RSK4 and with 
evidences that basal cellular kinase activity of ERK1/2 can already activate RSK4 to 30-50 % (20).  
The three structures have similar active site organisation and AMP-PNP coordination (fig. S12C). 
Specifically, the N1 and N6 of the AMP-PNP adenine ring form hydrogen bonds with the backbone of 
L155 and of D153, as well as hydrophobic interactions with L205, A103, V87 and L79. The position of 
the α- and β-phosphate groups is stabilized by interactions with the side chains of the conserved 
residues K105, N203, K221, T215 and F84. The γ-phosphate interacts with K200, which is 
indispensable for the formation of enzymatic intermediate during catalysis. The AMP-PNP 
phosphates are in an optimal alignment for transferring the γ-phosphate to the substrate (17) in all 
three structures. The major difference in the active sites as compared to a typical protein kinase is 
the contribution of residues from the βB-sheet motif, particularly K221. The residue K221 extends 
down from β10 of the βB-sheet, and inserts directly into the active site, interacting with D216 (part 
of the DFG motif) and with the β-phosphate of the AMP-PNP and the three together should 
coordinate a Mg ++ ion (due to resolutions limits, we have not been able to confidently place Mg ++ 
ions in the structure), which help the correct positioning required for ATP binding and catalysis (17). 
Furthermore, K221 produces an interaction network similar to that of K72 in PKA, known to be 
important in catalysis. This arrangement is almost identical to the active site of RSK2 NTKD (18) (fig. 
S12C), where mutations of K216, equivalent of K221 in RSK4, caused impaired RSK2 NTKD activity 
(18). Taken together, these structural data strongly confirm the importance of K221 for RSK4 
function. 
 
A unique feature of dephosphorylated and pS232 RSK4-NTKD structures is the presence of a second 
AMP-PNP molecule which could be modelled with full occupancy (Fig. 6C). This AMP-PNP contacts a 
symmetry equivalent molecule and is important for crystal lattice formation. It is located in a surface 
area absent in classical AGC kinases, created through structural rearrangement caused by formation 
of the βB-sheet and the displacement of the C-helix. The AMP-PNP molecule in the secondary site is 
stabilised by a network of hydrogen bonds with water molecules and the side chains of residues 
C234, H250, Q81, K86, R247, D225 and K113. C234 and H250 together with the β- and γ-phosphates 
coordinate in a "Zing Finger”-like way a Zn++ ion. This tetrahedral coordination clearly distinguishes 
this Zn++ ion from a Mg++ ion. This coordination is identical in the dephosphorylated and pS232 RSK4-
NTKD structures. We speculated that this unique surface is a “hot spot” (21) and represents a 
promising target for drug design. 
 
 
RSK4 hydrophobic motif interaction site  
 
Many AGC kinases possess a hydrophobic motif (HM), located C-terminal of the kinase domain, that 
is phosphorylated to achieve maximal activity (22). In classic AGC kinases the HM wraps around the 
N-lobe, where a phosphate-binding pocket is localized, and stabilizes the active conformation of the 
C helix (23) (24). For RSK1-3, phosphorylation of the HM - found within the linker region - acts to 
recruit PDK1, which then phosphorylates the NTKD activation loop, resulting in activation of these 
RSKs. However, because RSK4 activation is PDK1-independent (20), we investigated the role of the 
HM in this process. Due to the presence of the βB-sheet the phosphate-binding pocket of RSK4-
NTKD is rotated ≈50° clockwise compared to that of other AGC kinases. Moreover, this pocket is 
where we located the second AMP-PNP molecule (Fig. 6C). We used this information to guide a 
restrained docking simulation (25) using our RSK4-NTKD structure and a fully flexible phosphorylated 
peptide encompassing the HM sequence (NAHQLFKGF-pS-FVATSIAEE). HADDOCK (25) produced two 
clusters of solutions which represents 98.5 % of the water-refined models the software generated 
and the best one had a score of -189.0 +/- 18.2, a cluster size of 190 with RMSD from the overall 
lowest-energy structure of 1.5 +/- 1.2 Å and a Z score of -1. The most striking feature of the model 
generated by HADDOCK (26) is the position of the pS389 that occupies the same area of the γ-
phosphate of the second AMP-PNP molecule, supporting our hypothesis that the latter is mimicking 
the HM (Fig. 6D). Specifically, the pHM position is mainly stabilised by a large network of 
hydrophobic interaction, while the pSer 389 forms H-bonds with E54, K113, C234 and R247. Taken 
together, our bioinformatics studies identified a potential phosphate-binding pocket in RSK4-NTKD.  
 
Mathematical models based on the RSK4-NTKD structure predict an allosteric binding site 
 
To obtain structural information about trovafloxacin binding to RSK4 we tried soaking and co-
crystallisation experiments using both RSK4-NTKD and RSK4-NTKD S232E. Resulting crystals either 
did not contain trovafloxacin or failed to diffract. Consequently, as our wet-lab experiments 
suggested that trovafloxacin is an allosteric inhibitor, we adopted Markov Transient Analysis (MTA). 
This atomistic graph-theoretical approach can identify allosteric hotspots on the RSK4-NTKD without 
any a priori knowledge other than the location of the active site. MTA quantifies the speed at which 
a random walk diffuses on the atomistic protein graph constructed from interatomic strong and 
weak chemical interactions by computing the half-time t1/2 for each atom (27).  We applied MTA to 
our RSK4-NTKD structure to establish the specific pattern of propagation of perturbations originating 
from the active site and diffusing into the rest of the protein (Fig. 6F). Using quantile regression (28) 
(29)  on the computed t1/2, MTA identified a statistically significant hotspot (residues with ≤5% 
significance level) that corresponded to the second AMP-PNP binding site (Fig. 6G). The identified 
allosteric site exhibited a direct communication pathway with the active site (Fig. 6F), as confirmed 
in more detail through exhaustive computational alanine screening (fig. S13A-B). Each residue was 
individually alanized computationally to identify mutations that perturbed the communication 
between the active and obtained allosteric sites. Significant residues (one-sided, Z > 1.64, p < 0.05, 
red) under alanisation (fig. S14A) formed one of two different pathways connecting the active and 
allosteric sites (fig. S14B). Taken together, our data suggest that the second AMP-PNP binding site 
represents an allosteric site on the RSK4-NTKD. 
 
 
Trovafloxacin docking and impact on Markov transient propagation 
 
We performed molecular docking of Trovafloxacin using AutoDock Vina (30) around the site where 
the second AMP-PNP molecule sits in our crystal structures. This suggested that trovafloxacin bound 
to that site with a favourable energy of –8.1 kcal/mol (Fig. 6E), which corresponded well with our in 
vitro inhibition data. We noticed that trovafloxacin and the allosteric inhibitor positive controls 
sarafloxacin and tosufloxacin tosylate had a similar overall architecture and were predicted to bind 
RSK4 in a similar way (fig. S13C). In contrast, the non-inhibitor negative controls ciprofloxacin and 
clinafloxacin, which have a more liner structure, occupied a slightly different site on RSK4 (fig. S13D). 
This may be connected to the predicted 1.5 order of magnitude difference in the binding energy 
between RSK4 allosteric inhibitors (–8.3 and -8.4 kcal/mol for sarafloxacin and tosufloxacin tosylate, 
respectively) and non-inhibitors (–6.6 and -6.7 kcal/mol for ciprofloxacin and clinafloxacin, 
respectively). Comparison of the trovafloxacin docking model with the RSK4-NTKD X-ray structure 
showed that the naphthyridine and phenyl moieties of trovafloxacin occupied the same cavity where 
the adenine ring of the second AMP-PNP molecule sits, whereas the azabicyclo group pointed 
outwards and occupied the same area as the ribose and α-phosphate of the AMP-PNP (Fig. 6C and 
E). To further validate this binding pose, we repeated the molecular docking using alternative 
software, GLIDE (31). The top-ranked pose, nearly identical to the one obtained using AutoDock Vina 
(fig. S13E), had a binding free energy (MM-GBSA ΔGbind) of -31.93 kcal/mol.  
To assess the impact of trovafloxacin binding to the second AMP-PNP site, we again employed MTA 
to test the reverse propagation of perturbations originating from the allosteric site into the rest of 
the protein in the presence or absence of AMP-PNP and our inhibitor. Despite the close similarity of 
the binding for the two molecules, MTA revealed a marked change in the communication pathways 
originating from the trovafloxacin-binding site as compared to those originating from the AMP-PNP-
binding site (Fig. 6H). In particular, MTA revealed enhanced communication from the trovafloxacin 
site to the active site, whereas propagation from the AMP-PNP site displayed direct communication 
with the activation loop and lower lobe of RSK4 (fig. S13F). These data suggest that the binding of 
trovafloxacin would impact the active site, providing a rational for the activity of this compound on 
RSK4 activation. 
 
Determination of trovafloxacin’s binding site on RSK4 through hydrogen/deuterium exchange 
 
To gain further insight into the mechanism of action of trovafloxacin, we carried out 
hydrogen/deuterium exchange studies with RSK4 in the presence or absence of the drug. In this 
analysis, the protein is exposed to deuteriated water (D2O), which allows hydrogens on the protein 
backbone amides to be exchanged for deuterium. The exchange is stopped at various times by 
reducing the pH, the protein is digested with pepsin, and the deuterium content of peptides 
determined by mass spectrometry (32). Because the rate of exchange is dependent on the tertiary 
structure (degree of hydrogen bonding) and solvent accessibility of amide hydrogens, such studies 
can yield information about binding or protein conformation, which are revealed by changes in the 
kinetics of deuterium incorporation into specific amino acids/peptides (33) (34). 
Figure 6I shows a difference plot in daltons of each RSK4 peptide induced by the presence of 
trovafloxacin, averaged over all replicates and time points. Three regions, each covered by peptic 
peptides (fig. S14A), showed a reduction in exchange.  One of these regions (533-552) was towards 
the NTKD’s C-terminus, whereas a second was adjacent to this in the NTKD kinase C-terminal region 
(627-636). A third region (246-279) N-terminal to the NTKD also showed reduced uptake of 
deuterium, but was outside of any predicted domain. The butterfly plot indicates that all three sites 
showing reduced uptake are in regions of sequence that are more exposed to bulk solvent. From the 
uptake kinetics these sites are predicted to be unstructured loops rather than α-helices or β-sheets 
(fig. S14B). The positions of protection suggest that trovafloxacin is not binding directly in the active 
or nucleotide binding sites of RSK4, but instead has an allosteric effect, inducing a conformational 
change in the overall structure of RSK4. The overlap between the docking data, the Markov transient 
analysis and the deuterium exchange results suggest that the 627-636 stretch in our tagged protein 
(aa 398-407 on RSK4) corresponds to the region of trovafloxacin binding, whereas the other 
protected sites undergo subsequent conformational changes as a result of the allosteric nature of 
this region. Other  minor differences observed were close to the background error of the system and 
therefore were considered non-significant. 
 
Trovafloxacin and the role of the HM in RSK4 activation 
 
Our data suggest that both trovafloxacin and the HM interact with the second AMP-PNP binding site 
on the RSK4-NTKD (Fig. 6C-E). As MTA predicts this region is an allosteric site, we hypothesized that 
the HM may affect the autophosphorylation rate of RSK4-NTKD. To test this hypothesis, the RSK4-
NTKD was incubated in presence of saturating amount of ATP/Mg2+ alone or with the HM synthetic 
peptides HP (NAHQLFKGFSFVATSIAEE) or pHP (NAHQLFKGF-pS-FVATSIAEE) corresponding to 
residues 380-398 of RSK4 (fig. S15). RSK4-NTKD autophosphorylation was measured over time using 
a phospho-Ser232-specific antibody. Incubation with pHP promoted RSK4-NTKD 
autophosphorylation compared to that of the HP or the RSK4-NTKD alone (fig. S15). Taken together, 
our data suggest that the phosphorylated HM binds RSK4-NTKD to increase its autophosphorylation 
rate. This explains how trovafloxacin inhibits RSK4 activation through preventing HM docking to the 
phosphate-binding pocket of the kinase. 
 
Trovafloxacin inhibits tumour growth and sensitises tumours to drug treatment in vivo 
 
Having shown how trovofloxacin might mechanistically impair RSK4 activation and that it reproduces 
the biological effects of RSK4 downregulation in vitro, we assessed the activity of this drug in vivo. 
Luciferase-encoding A549 cells (A549-Luc) were injected subcutaneously into nude mice. Once 
tumours became palpable, the mice were randomised to receive or not daily oral gavage of 
trovafloxacin (30 mg/kg) and weekly intraperitoneal injections of cisplatin (5 mg/kg) for 14 days. 
Bioluminescent whole-animal imaging performed on the first and last days of treatment after 
injection of luciferin (Fig. 7A, fig. S16A) shows that, as for RSK4 CRISPR cells, administration of 
trovafloxacin significantly (p<0.05) decreased tumour growth compared to vehicle-only treatment 
and the effect of the trovafloxacin/cisplatin combination was superior to that of cisplatin alone 
(p<0.01). This potentiation of cisplatin response was consistent with the statistically significant 
increase in caspase 3 cleavage observed in tumour samples from animals treated with the drug 
combination as compared to  trovafloxacin (p<0.001) or cisplatin alone (p<0.01) (Fig. 7B, fig. S16B). 
The ability of trovafloxacin to potentiate response to cisplatin was further confirmed in the 
KRASV12/TP53-/- (KP)-driven genetically-engineered mouse model where spontaneous lung 
adenocarcinoma tumours are triggered through adenoviral Cre-recombinase delivery (35) (Fig. 7C-F). 
This was consistent with trovafloxacin-induced molecular changes in cells isolated from KP tumours, 
such as decreased cIAP2 expression and increased caspase 3 cleavage, similar to those seen in A549 
cells (Fig. 7C, fig. S16C), whereas the RSK4 non-targeting compounds ciprofoxacin failed to elicit such 
changes. The trovafloxacin/cisplatin combination was associated with decreased tumour number 
and volume as assessed by macroscopic observation (Fig. 7D) and by µCT scanning (Fig. 7E-F, fig. 
S16D, movie S1 and S2). For bladder cancer, as we lacked a genetically engineered mouse model, we 
instead employed a recently described human cancer explant system (36). We demonstrated that 
the cisplatin/trovafloxacin combination was beneficial in 3 out of 4 patient-derived bladder cancer 
explants, with synergistic effects observed in two and additive effects in one (fig. S16E). The last 
patient’s tumour showed extreme sensitivity to cisplatin alone so the added benefit of trovafloxacin 
could not be assessed. Collectively, our results suggest that administration of RSK4-targeting 
floxacins may provide clinical benefit in patients with lung adenocarcinoma and bladder cancer. 
 
Levofloxacin inhibits RSK4 in vitro and prolongs survival of patients with cancer 
 
Because floxacins are frequently used in the clinic to prevent infections in patients undergoing 
chemotherapy we wondered whether this could be associated with improved OS. A large placebo-
controlled randomised phase 3 study (SIGNIFICANT Trial) (fig. S17) demonstrated that levofloxacin 
reduced infective complications in patients undergoing chemotherapy in several cancer types, 
including lung and bladder cancer (37). HTRF assays revealed that levofloxacin inhibited RSK4 
activation, resulting in decreased cellular cIAP1 and cIAP2 expression (fig. S18A-B) at concentrations 
achievable from the dose given in the clinical trial (38, 39). We therefore undertook a retrospective 
exploratory analysis of 1565 SIGNIFICANT trial patients to investigate whether the use of 
prophylactic levofloxacin during chemotherapy treatment had an effect on long-term OS. In patients 
adhering to trial treatment (n=937), OS was significantly longer for those taking levofloxacin 
compared to placebo (median OS 72 versus 59 months, respectively, HR 0.83; 95% CI 0.69-0.999; p 
=0.048; fig S18C-left). Analysis of non-adherent patients (n=543) further substantiated this 
levofloxacin effect by showing no difference in OS (HR=1.11; 95% CI 0.89-1.40; p=0.36; fig S18C-
right). Sensitivity analysis showed that excluding patients who died during treatment did not change 
the conclusions and thus this improvement in OS could not be due to a reduction in infective deaths 
due to the antibacterial effect of levofloxacin. The hazard ratio was further improved for lung and 
bladder cancer patients compared to the entire cohort (fig. S18D). Collectively, these results provide 
intriguing clinical evidence that a RSK4-targeting floxacin might also potentiate the effects of 




Our findings demonstrate the role of RSK4 as a tumour promoter in lung adenocarcinoma and 
bladder cancer cells. Overexpression of this kinase lead to drug resistance and increased cell 
migration in lung and bladder cancer cell lines in vitro, and correlated with poorer survival in lung 
adenocarcinoma patients. Conversely, silencing this kinase using RNA interference or CRISPR-
mediated knock-out, sensitised cells to chemotherapeutic drugs, and prevented invasion in vitro and 
in vivo. Our data were consistent with findings in renal carcinoma (6, 7), but conflicted with the 
proposed role of RSK4 as a tumour suppressor in breast cancer (3, 4, 40). Several explanations might 
account for this discrepancy including a tissue-specific role of RSK4 or differential expression of RSK4 
splice variants as at least two protein-coding transcripts for RSK4 are reported in Ensembl; RPS6KA6-
201 and RPS6KA6-204. Further work is necessary to elucidate these seemingly conflicting tissue-
specific data. 
 
Our observations led us to hypothesize that a selective RSK4 inhibitor might represent a valuable 
therapeutic tool in the treatment of lung and bladder cancer. Indeed, RSK4 protein is overexpressed 
in the majority of lung malignancies, especially in adenocarcinoma, but undetectable in normal lung 
and poorly expressed in most other tissues (1). Similarly, bladder cancer samples show increased 
RSK4 mRNA expression compared to matching normal tissue. Hence, RSK4 inhibitors could exhibit 
some degree of specificity for these cancers. Moreover, the fact that RSK1, unlike RSK4, is well 
expressed in a variety of normal human tissues (1) may suggest that a RSK4-selective, rather than 
pan-RSK, inhibitor would be preferable. In support of this, our previous research showed that RSK1 
silencing promoted invasion of lung cancer cells (8), an effect also seen in A549 cells with the pan-
RSK inhibitor SL0101 but not the pan-RSK inhibitor BI-D1870 (41). Furthermore, we showed here 
that RSK1 in contrast to RSK4 silencing rendered lung and bladder cancer cell lines chemo-resistant. 
S, while silencing RSK2 or RSK3 either led to inconsistent biological outcomes across cell lines or had 
no impact on cell migration and drug response (8, 9). Thus, it appears crucial that a therapeutically 
useful RSK4 inhibitor should avoid targeting RSK1 at the least.  
 
Prior crystal structure data for the NTKDs of RSK1 and 2 (18) compared to that shown for RSK4 in the 
present paper reveal that the active sites for all three kinases are essentially identical. Consequently, 
the best hope of a RSK4 selective inhibitor might be a molecule that binds allosterically rather than 
in an ATP competitive fashion. The floxacins were originally developed as antibiotics (42) but our 
results show that some members of this family appear to selectively inhibit the activation of RSK4 
through allosteric binding. This occurs via a second AMP-PNP binding site not conservered in other 
AGC kinases providing a likely mechanism for RSK4-selectivity. Several questions arise from our 
observations including whether the antibiotic function of floxacins is necessary for inhibition of RSK4 
activation and whether floxacins could be re-purposed for use as an anticancer agent in the clinic? 
 
A clue to answering the first question is provided by our finding that whilst all floxacins are 
antibtioics, several family members such as ciprofloxacin and danofloxacin fail to impair RSK4 
activation. This combined with the information on the RSK4 binding site for active floxacins should 
enable chemistry to derive new allosteric inhibitors lacking the antibiotic function but nevertheless 
maintain RSK4 targeting. Loss of floxacin antibiotic function could be clinically advantageous in 
potential cancer therapy. This is because prolonged use of these agents can cause serious antibiotic-
induced complications including severe diarrohea due to clostridium difficile toxin as well as 
facilitating a rise in bacterial antibiotic resistance (43, 44). It is unknown whether dissociation of 
antibiotic from RSK4 targeting effects of floxacins will be possible and whether this would remove all 
unwanted side-effects, but it seems likely it would eliminate the diarrhoea and issues related to 
bacterial resistance. Intriguingly, results from several studies in cancer patients receiving 
chemotherapy provide tentative hope that at least one RSK4 targeting floxacin, levofloxacin, is well 
tolerated (44). Whilst there is good data to show that use of floxacins such as levofloxacin, prevents 
neutropaenic sepsis and it’s related acute deaths in cancer patients undergoing chemotherapy, 
there was no evidence to inducate that this might improve longer-term survival. Data presented 
here suggest that at least for levofloxacin, cancer patients taking this drug as part of the 
SIGNIGICANT trial do survive longer leading us to speculate that this benefit could be due to 
inhibition of RSK4. However, other reports show that floxacins may exert distinct effects on cancer 
cells such as impaired mitochondrial function and oxidative stress responses (45) which may be 
independent of RSK4 targeting so further work is needed.  
 
So how could RSK4 inihibtion impair cell migration/invasion and enhance chemotherapeutic effects 
in lung and bladder cancer cells? Prior data in other RSKs across several cancer types have not 
revealed any clear mechanistic data for RSK4 (46). Here, we have provided some evidence that RSK4 
enhances resistance to chemotherapeutic drugs at least in part by increasing cIAP2 protein levels 
through a transcriptional mechanism. However, how enhanced transcription of its mRNA is achieved 
is not yet clear although this is not dependent on NFkB. We also provide some evidence that RSK4 
phosphorlyates Ser89 of p300 likely leading to increased RELA nuclear localisation and enhanced 
activity of NFkB thereby increasing EMT and metastatic behaviour.  
 
There are several limitations of our study and some are now discussed. Firstly, we have not provided 
a formal demonstration of trovafloxacin specificity for inhibiting RSK4 as opposed to RSK1 activation. 
This would require the development of an in vitro RSK1 activation assay which is complicated by the 
fact that both ERK2 and PDK1 would be needed and our attempt to develop this have so far failed. 
However, our preliminary data show that trovafloxacin does not inhibit the activation of RSK1 in 
cells. Secondly, further research is required to provide definitive proof of endogenous interaction 
between RSK4 and p300 and to conclusively show how this mediates the EMT changes observed. 
Thirdly, although our prior research (8) and results shown here demonstrate that RSK1 and RSK4 
have opposite biological outputs in regulating invasion and chemo-sensitivity of lung cancer cells, 
the downstream mediators responsible are currently unclear.  Large scale omics analysis assessing 
the effects of RSK1 and RSK4 silencing and over-expression are required to identify potential 
discriminating effector pathways. Forthly, some, but not all floxacins, are potent RSK4 activation 
inhibitors. However, our current data do not provide sufficient structure-activity relationship 
information to clearly define the reason behind this selectivity. Finally, the re-analysed SIGNIFICANT 
trial data do not establish that the reason for improved survival with levofloxacin is anything to do 
with RSK4 inhibition. Indeed, a proof of concept trial is urgently needed to test this hypothesis in 
patients.  
 
In summary, we have identified RSK4 as a mediator of tumour metastasis and chemotherapy 
resistance in vitro and in vivo and as a potential therapeutic target in lung and bladder cancer. Our 
drug screen identified certain floxacins as RSK4 allosteric inhibitors with our structural and in-silico 
modelling work providing a potential site for their binding. Collectively, our data suggest that RSK4-
targeting floxacins such as levofloxacin could be re-purposed for proof-of-concept combination 
studies with existing chemotherapeutics in patients with lung and bladder cancer. 
 
Materials and Methods 
Study design 
The aim of this study was to highlight the role of RSK4 in invasiveness and chemoresistance of lung 
and bladder cancer cells and show how targeting this kinase may represent an effective therapeutic 
strategy for these cancers. We silenced or induced RSK4 expression in lung AdCa and bladder cancer 
cell lines and studied the molecular mechanisms involved in modulating the above processes using 
molecular biology, biochemical, and phenotypic analysis. We also screened for and identified RSK4 
activation inhibitors that reproduced the molecular and phenotypic changes observed through RSK4 
silencing. We validated our findings through varied corresponding mouse or explant models and 
proposed mechanism of action for the inhibitors based on structural, mathematical, and biochemical 
approaches. For in vitro or cell culture experiments, at least three independent biological replicates 
per condition were used for statistical analysis. For animal experiments, the work was performed 
under UK Home office approved project licenses and in accordance with institutional welfare 
guidelines. Analysis of Ct scan images to measure changes in tumour volume was done blinded. 
Animals were treated without knowledge of anticipated outcomes. No data points were removed as 
outliers.Cohort sizes were selected based on prior work using the same models and corresponding 
power analyses to provide power of 0.8 and P<0.05. Tumour-bearing animals were randomized 
before treatment. Animals showing no tumour growth prior to treatment administration were 
excluded from further analysis. Last, we searched for prior clinical trials using floxacins in cancers 
including lung and bladder to ask if there was any evidence that use of such antibiotics might extend 





Statistical testing was performed using Prism (GraphPad) or Excel (Microsoft). Most experiments were 
analyzed by one-way ANOVA with Tukey’s, Dunnett’s or Benjamini-Hochberg correction multiple 
comparison or with two-tailed unpaired Student’s t-test. For datasets where the reduced count did 
not allow normality test, a normal distribution was assumed on the basis of data distribution. For all 
statistical analyses, significance was accepted at the 95% confidence level (P < 0.05) and significance 
levels indicated. Error bars in all figures represent the SEM as a measure of the accuracy of the mean 
values shown unless otherwise stated.  
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Figure 1: RSK4 downregulation sensitises lung and bladder cancer cell lines to chemotherapy. (A-C) 
A kinome siRNA screen reveals modulators of taxol and cisplatin response in T24 bladder cancer 
cells. (A) Dot plot of ratio of cell number change in response to drug treatment for cells silenced for 
individual targets over those transfected with non-targeting (NT) sequences. (B) Venn diagram of 
targets modulating response to cisplatin with or without taxol. (C) Number of validated targets in 
T24, TCCSUP, and J82 bladder cancer cells out of the 23 screen hits. (D) Effect of siRNA-mediated 
silencing in T24 or A549 or (E) CRISPR-mediated knock-out of RSK4 in A549 cells on cell survival to 
cisplatin (T24-3.5 µM and A549-12.5 µM) or taxol (T24-40 nM and A549-58 nM). (E-upper) Lysates 
from RSK4 CRISPR clones (#1,#2) analysed by Western blotting (WB) for RSK4 knock-out efficiency. 
(E) #1 and #2 refer to two separate clones of RSK4-CRISPR cells. (F) RSK4 silencing effect on drug-
induced caspase-3/7 activation and (G) DNA damage in T24 and A549 cells. Cells transfected with 
RSK4-siRNA for 48h were treated with cisplatin or taxol and substrate-based caspase activity or 
γH2AX expression measured. (H) RSK4 silencing effect on baseline apoptotic pathway activity in 
A549 cells. (I) RSK4 downregulation effect on BCL2, cIAP1, and cIAP2 expression. (J) A549 cells 
treated with siRNA for 48h analysed by RT-qPCR. (A, D and E) Cell number assessed by Crystal violet 
staining and normalised to the corresponding control condition. (A) Data are average of four 
individual siRNA sequences per target. (D-J) Data representative of n=3. (D-G and J) Data are mean ± 
SEM of n=4. (D, H, I) Tubulin or vinculin was used as loading control. 
 
Figure 2: RSK4 downregulation inhibits the pro-metastatic program. (A-G) A549 and T24 cells 
transfected with/without RSK4, RSK1 and non-targeting (NT) siRNAs or RSK4 and empty-vector (EV) 
cDNAs were analysed 48h or 72h later. (A) Random-walk assays determined cell speed (left) and 
single-cell trajectories (right). (B) Cells were covered with collagen-I and overlaid with EGF for 
chemotaxis. 48h later, cells were stained with Cytox Green before confocal imaging to determine the 
extent of invasion. Data are mean ± SEM of 36 fields-of-view/condition. (C) Cells were stained for 
actin before fluorescent microscopy. Images are representative of 36 fields-of-view/condition. Scale 
bar: 10µm. (D) Cell lysates were analysed by SDS-PAGE/WB. Vinculin was used as loading controls. 
(E) Cells transfected with a RelA-Firefly luciferase reporter construct and a Renilla luciferase control 
vector were then transfected with siRNAs and lysates and analysed for Firefly luciferase activity 
normalised to the Renilla luciferase control. (F) cytoplasmic (Cyto) and nuclear (Nuc) fractions were 
analysed by SDS-PAGE/WB. Ubulin and Lamin B were used as loading controls. (G) Cell lysates were 
analysed by SDS-PAGE/WB. HSP90 was used as a loading control. (H) Recombinant p300 (1µg) was 
mixed with or without recombinant RSK4 (200ng) and γATP for 5 min prior to SDS-PAGE/WB analysis. 
(I) A549 and T24 cells transfected with/without RSK4, RSK1 and non-targeting (NT) siRNAs were split 
equally 48h later between adherent and ultra-low adhesion plates for 24h prior to re-adhesion. Cell 
numbers were determined by Crystal violet staining and ratio of suspension-treated to only-
adherent cultures represented as mean ± SEM of n=4. Data are representative of at least biological 
triplicates. Statistics: Student’s t-test (B, I and E) and ANOVA (A) with n.s.; not significant, *; p<0.05, 
**; p<0.01, ***; p<0.001. 
Figure 3: RSK4 is overexpressed in lung cancer and correlates with poor survival in patients with 
lung adenocarcinoma. (A-C) Normal (n=25) and cancerous (n=183) lung FFPE samples were stained 
with H&E or a RSK4 antibody followed by 3,3′-Diaminobenzidinedevelopment. (A-left) Examples of 
RSK4 staining in normal lung and RSK4-negative and -positive adenocarcinoma (AdCa) samples. Scale 
bar: 30 µm. (A-right and B) Percentage of samples showing positive (pos) or negative (neg) RSK4 
staining shown for (A) all primary (Iary) lung cancer samples or (B) lung cancer (LC) subtypes. SCC; 
squamous cell carcinoma, SCLC; small-cell LC. (C) RSK4 staining semi-quantitative scores for each LC 
subtype. (D) Comparison of RSK4 mRNA expression between AdCa, SCC, and normal lung samples in 
TCGA RNA-Seq data. Statistics: t-test; ns, not significant. (E) Overall survival of patients with AdCa or 
SCC with high or low tumour RSK4 mRNA expression. Cut-off: median value. (F) Comparison of post-
mortem matched primary and metastatic AdCa (n=26) and SCC (n=20) lesions for RSK4 IHC staining 
scores. Percentage of cases where metastatic lesions expressed more (Met>Primary) or less 
(Met≤Primary) RSK4 than the primary site. Average IHC scores are shown. Statistics: (C) ANOVA; ***; 
p<0.001, **; p<0.005 and *; p<0.05. 
Figure 4: RSK4 downregulation impairs growth of lung adenocarinoma xenografts, sensitises to 
chemotherapy, and reduces metastatic potential of lung cancer cells. (A-B) Non-targeting (NT) or 
RSK4 CRISPR A549 cells were injected subcutaneously in nude mice and tumour growth rate (A) or 
fold volume change at Day-46 following treatment cycle with/without cisplatin (B) monitored. (C) 
A459 NT or RSK4 CRISPR cell clone #1 were injected through the tail vein of SCID mice. Animals were 
sacrificed 2 months later and their lungs paraffin-embedded. 10 sections (each separated by 60µm) 
were H&E stained and numbers of (lower), and lung area colonised by (upper) tumour nodules 
quantified. Upper: dots represent individual lung sections. Statistics: ANOVA (A-B) and Student’s t-
test (C). n.s.; not significant, *; p<0.05, **; p<0.01, ***; p<0.001. 
Figure 5: Trovafloxacin, an inhibitor of RSK4 activation, reproduces the biological effects of RSK4 
silencing. (A) Diagram of the drug screening process. (B) Moxifloxacin, trovafloxacinand ciprofloxacin 
differ in their ability to inhibit activation of RSK4 by ERK2 in HTRF assays. (C-D) A549 cells incubated 
with the indicated concentration of floxacin for 1h were treated with cisplatin (12.5 µM) for 72 h (C) 
or 24 h (D). (C) Cell viability determined using Alamar Blue. (D) Caspase activity determined using a 
substrate-based fluorigenic assay. (E) Relation of cisplatin sensitisation by trovafloxacin in A549 cells 
to RSK4 expression. NT; non-targeting siRNA, EV; empty-vector DNA, oeRSK4; overexpressed RSK4, 
si5’UTR-RSK4; 5’UTR RSK4 mRNA-directed siRNA. (F) Lysates from A549 cells treated with or 
swithout trovafloxacin (Trova) for 24 h were analysed by SDS-PAGE/WB. Vinculin used as loading 
control. (G) Random cell migration or (H) 3D collagen-I invasion in A549 cells treated with indicated 
inhibitors (10 µM). Dano; danofloxacin, Tosu; tosufloxacin tosylate, Moxi; moxifloxacin. (I) 
Trovafloxacin binding tos inactive (dephosphorylated, APO) and not fully-active (ATP) RSK4-NTKD. 
Tm-shift assay performed over the indicated temperature range (left) and parameters recorded 
(right). (B-H) Results representative of at least three independent repeats. Data are mean (B-D and F) 
or median (G-H) of n=4 ± SEM. Statistics: ANOVA. *; p≤0.05, **; p≤0.01, ***; p≤0.001. 
Figure 6: RSK4-NTKD structure and trovafloxacin binding site prediction. (A) Structure of 
dephosphorylated RSK4-NTKD. (B) Overlay of dephosphorylated RSK4-NTKD and PKA structures 
showing the characteristic βB-sheet and α2-helix of RSK4-NTKD as opposed to the C-helix of classical 
AGC kinases. (C-E) Docking of second AMP-PNP (C), the phospho-HM peptide (D) and trovafloxacin 
(E) to the RSK4-NTKD. Inserts: view of interaction residues. Colours: βB-sheet; red, activation; teal, 
H-bonds; yellow dotted lines. AMP-PNP, trovafloxacin and hydrophobic motif FXXF-pS-F residues 
coloured by element. Key binding site residues shown in ball-and-stick. (F-G) Identification of an 
allosteric hotspot in RSK4 through Markov transient analysis. (F) Propagation of a random walk on 
the protein graph, originating at the active site showingactive site and a hotspot where trovafloxacin 
and AMP-PNP bind. The evolution of the probability distribution (shown at t=0, 500, 1000 sec; atoms 
coloured from white to red with increasing probability) is shown relative to the trovafloxacin binding 
site and the upper and lower lobes of RSK4. (G) Top: From the RSK4 structure and location of its 
active site, the pathway is extracted through statistical quantile regression of the Markov transient 
times of the random walk, t1/2, against distance. Low quantile scores indicate residues highly 
connected to the active site (relative to their distance). Bottom: Quantile score (pR) of each residue 
mapped onto RSK4’s surface (different views). Residues below the 2% quantile connect the active 
(black ellipse) and the allosteric (green ellipse) sites. (H) The propagation of the random walk 
originating from AMP-PNP or trovafloxacin binding at the allosteric site exhibits different 
communication pathways. (I) Deuterium exchange mass-spectrometry for RSK4 incubated with or 
without trovafloxacin. Difference plot obtained by subtracting the incorporation of deuterium in the 
absence versus in the presence of trovafloxacin. Colours: Experimental error; light grey, other 
colours represent different D2O incubation times.  Upper half of graph; more exposed regions, lower 
half; protected regions. RSK4 amino acid numbers are given for regions showing significant 
protection or exposure as indicated by being above or below the dotted red and blue lines (98% 
confidence limit). 
Figure 7: Trovafloxacin enhances cisplatin efficacy in A549 xenografts and KRASV12/TP53-/- (KP)-
driven genetic  mouse models. (A-B) Nude mice injected subcutaneously with luciferase-expressing 
A549 cells treated with or without trovafloxacin and  cisplatin once tumours reached 0.5cm in any 
dimension. (A) Left: representative images from each condition showing luciferase signal at day 0 
and 14. Right: Percent tumour volume change at Day 14. Red bar; median. Statistics: Student’s t-test, 
*; p≤0.05, **; p≤0.01, ***; p≤0.001. (B) IHC of end-point tumours for caspase-3 cleavage. (C) 
Differential effect of trovafloxacin and ciprofloxacin on RSK4 phosphorylation (pRSK4-S232), cIAP2 
expression and cleaved (Clv) caspase-3 in a cancer cell line isolated from KP tumours (D) 
Representative images of lungs from treated KP animals. Green stars; examples of lung tumour 
nodules in the vehicle-only condition. (E) Representative µCT scans from vehicle-only and 
combination-treated KP animals before treatment and at end-point. Individually tractable tumours 
indicated by numbers and green circles. (F) Percent volume change in individually tractable tumours 
in KP mice determined by differential analysis of CT-scans before treatment and at end-point. Dots 
represent individual tumours. Red line: median ± SEM. Statistics: ANOVA; *; p≤0.05, **; p≤0.01, ***; 
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NSCLC subtype Cases (%) Average IHC score
Met > Primary Met ≤ Primary Met > Primary Met ≤ Primary
Adenocarcinoma 52 48 55.23 43.43




















#1 #2 #3 #4 #5 #6 #7 #8 #9 #10 #1 #2 #3 #4 #5 #6 #7 #8 #9 #10
#1 >10 >10 >10 >10 >10 >10 >10 >10 >10 >10 #1 4 4 4 4 4 5 5 5 5 5
#2 >10 >10 >10 >10 >10 >10 >10 >10 >10 >10 #2 1 1 1 1 1 1 0 0 0 0
#3 >10 >10 >10 >10 >10 >10 >10 >10 >10 >10 #3 1 1 1 1 0 0 0 1 1 1
#4 >10 >10 >10 >10 >10 >10 >10 >10 >10 >10 #4 4 4 4 4 5 6 7 6 5 5
#5 0 0 0 0 0 0 0 0 0 0 #5 1 1 1 1 1 1 1 1 1 1
#6 >10 >10 >10 >10 >10 >10 >10 >10 >10 >10 #6 2 2 2 2 0 0 0 0 0 0
#7 >10 >10 >10 >10 >10 >10 >10 >10 >10 >10 #7 1 2 2 2 4 4 4 3 3 3















































































































pIC50= 5.20 ± 0.22
150
-9 -8 -7 -6 -5 -4 -3
Log.[Ciprofloxacin].M
-9 -8 -7 -6 -5 -4 -3
pIC50= NA
Log.[Trovafloxacin].M
-9 -8 -7 -6 -5 -4 -3
pIC50= 5.59 ± 0.22
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APO+Trova (100μM) 36.41 ±0.01
ATP (1mM) 47.91 ±0.03
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SUPPLEMENTARY MATERIALS AND METHODS  
 
Cell  lines and culture: Non-small cell lung cancer (A549, H1299, EKVX and HOP62) and bladder 
cancer (T24, TCCSUP and J82) cells were cultured in DMEM/10% foetal bovine serum (FBS) at 37°C, 
10% CO2.   
 
RNA interference kinome screen: Cells were transfected with siRNA (35 nM) using Lipofectamine 
RNAi-Max (Invitrogen), according to the manufacturer’s instructions, for 48 h to allow for target 
silencing prior to subsequent treatment. The Kinome siRNA library v2.0 (Qiagen) targeted 691 
proteins with 4 individual oligonucleotide sequences/target. siRNAs targeting PLK1 were used as 
internal control for transfection efficiency across the screen. Luciferase-targeting (Dharmacon) 
oligonucleotides were used as negative controls. 48h after transfection, cisplatin and taxol were 
added or not to the cells to achieve their IC50 of respectively 3.5μM and 40nM. 48 h later, the plates 
were subjected to Crystal violet staining. Data were normalised to the readings obtained for the 
corresponding plate’s Luciferase siRNA condition. Hit selection for targets sensitising or antagonising 
drug treatment was performed as previously (48). Validation experiments for screen hits used 
siRNAs from Dharmacon. Specific siRNA sequences used to target RSK4 can be found in table S2. 
Individual siRNAs transfections: 20nM siRNA oligonucleotides (Dharmacon) were transfected using 
Oligofectamine 3000 (ThermoFisher) according to the manufacturer’s instructions. The siGENOME 
Non-targeting siRNA Pool #2 (Dharmacon) was used as non-targeted control. 
 
Plasmid DNA transfection 
Cells were transfected with Lipofectamine 3000 (Invitrogen) following the manufacturer’s 
instructions and used for experiments 24 h later when expression is maximal. The active RELA (T7-
RelA S536E - Plasmid #24156 (49)), cIAP1 and cIAP2 (gifts from Jon Ashwell - plasmid # 8311 and 
plasmid # 8338, respectively(50)) plasmids were obtained from Addgene. RSK4 transcript variant I 
(NM_014496.5) ORF was PCR-amplified using RSK4-GFP as template (pLPS-3’EGFP backbone; Arizona 
State University plasmid repository, AZ, USA), and primers introducing a 5’ XhoI restriction site prior 
to the start codon and a 3’ EcoRI restriction site after the stop codon. Double digested PCR products 
(XhoI/EcoRI) were cloned into a pLPC vector containing a FLAG-HA-HA tag (FH2) at the N-terminus, 
kindly provided by deLange Lab (The Rockefeller University, NY, USA). 
 
Crystal violet staining 
Cells were fixed in 4% paraformaldehyde (PFA) and stained in 0.02% crystal violet solution for 15 min. 
Plates were washed in water and air-dried. Crystal violet-precipitates were solubilised in 10% (v/v) 
acetic acid (30 min, room temperature, gentle shaking) and absorbance measured at 595 nm. 
 
Caspase 3/7 activity assay 
The Caspase-Glo 3/7 Assay (Promega) was performed according to the manufacturers’ instructions. 
Briefly, 100 µl of Caspase-Glo 3/7 reagent was added per 96-well and luminescence measured after 
15 and 60 min of incubation at room temperature (PHERAstar microplate reader). 
 
Cell motility assay 
1.103 cells were plated in 96-well plates and time-lapse imaging performed for 18 h (1 image/10 min) 
using a Zeis Axiovert microscope driven by Metamorph (Molecular Devices). Cells were tracked using 
Image J and tracks analysed in R.  
 
Actin cytoskeleton staining 
Cells in 96-well plates were fixed with a 4% PFA for 20 min, permeabilised with 0.1% Triton X-100 in 
PBS for 5 min, and blocked using 3% Bovin Serum Albumine (BSA) in PBS. Actin was stained with 
Alexa Fluor 488-Phalloidin (Molecular Probe) and nuclear DNA revealed using DAPI (Molecular 
Probe). Images for 36 fields per well were acquired using an ImageXpress high-content imager 
(Molecular Devices). 
 
qRT-PCR validation of target down regulation 
Total cellular mRNA was extracted using Purelink RNA kit (Invitrogen) and converted into cDNA using 
High Capacity Reverse Transcriptase kit (Applied Biosystems). qRT-PCR was performed using Fast 
SYBR green master mix (Applied Biosystems) with gene specific primers on ABI 7900 HT real-time 




Cellular proteins were extracted using a Radio immunoprecipitation assay buffer (RIPA) (50 mM Tris-
Cl, pH 7.4, 0.1% SDS, 0.1% sodium deoxycholate, 1% Triton X-100, 150 mM NaCl, 2 mM EDTA, 5% 
Glycerol supplemented with protease inhibitors cocktail tablets (Roche Diagnostics), 10 mM 
βGlycerophosphate, 1 mM sodium orthovanadate, 10 mM sodium fluoride). Equal protein amounts 
were diluted in 2x Laemmli buffer, boiled for 5 min and analysed by SDS-PAGE/Western blotting 
using the relevant antibodies. For details of antibodies used, see table S4. 
 
In vitro kinase assay 
1 μg recombinant p300 (Abcam) was incubated with 200 ng recombinant RSK4 in Kinase Buffer (50 
mM HEPES, 10 mM MgCl2, 2 mM DTT, 5 mM β-glycerophosphate, 0.1 mM Sodium orthovanadate). 
Reactions were started by adding 2 mM ATP and pursued for 30 min before termination in SDS-
sample buffer. 
 
RelA reporter assays 
Cells were transfected with a RelA-driven firefly luciferase construct together with a CMV-driven 
Renilla luciferase construct used for normalisation of the firefly luciferase signal. Detection of 




1.104 cells were plated in 96 well-plates for 24 h prior to being covered with rat tail Collagen I (BD 
Bioscience) (3mg/ml final) in DMEM/1% FCS. After 4 h, 25 µl of DMEM/1% FCS were placed above 
the gel. 25 µl of DMEM/1% FCS with 200 ng/ml EGF were added 24 h later. Cells were allowed to 
invade for 48 h. The gels were fixed in 4% PFA and cell nuclei revealed using Cytox Green (Molecular 
Probes). Nine stacks of 210 µm (4 µm intervals) were acquired per well with a Zeiss 7.10 invert 
confocal microscope. Stacks were analysed with ImageJ. 
 
Anoikis assay 
Cells transfected in 96-well plates with the relevant siRNA for 48 h were trypsinised and the content 
of each well split equally between an ultra-low attachment and a normal-adhesion 96-well plates 
(Corning). 18 h later, the content of the ultra-low attachment plate was transferred to a normal-
adhesion 96-well plate and left to adhere prior to Crystal violet staining. The absorbance of plates 




Post-mortem homemade tissue microarrays (TMA) containing syngenic primary tumour/metastasis 
samples from 98 patients was prepared (Ethic Ref: 06/Q0406/154). For full details on this TMA, see 
Supplementary Methods. Commercial TMAs (LC10010, LC1006, LC1201) containing 64 AdCa, 51 SCC, 
56 SCLC and 25 normal lung samples were purchased from US Biomax Inc. IHC was performed using a 
RSK4 antibody (Sigma Prestige) at 1/50 dilution. A semi-quantitative IHC score was used as previously 
described (51). Signal specificity was determined using RSK4-silenced paraffin-embedded A549 cells 
(fig. S4A). 
 
In vitro recombinant kinases assay screen 
Trovafloxacin (10 µM) was tested in an in vitro kinase assay using a panel of tyrosine and 
serine/threonine kinases as previously published (52). 
 
 
Generation of CRISPR RSK4 A549 cells 
The protocol used for the CRISPR/Cas9 system was as reported earlier (53). The backbone vector 
pX458, pSpCas9(BB)-2A-GFP was a gift from Feng Zhang (Addgene plasmid #48139). Two guide RNA 
sequences were designed to target RSK4 gene (5’-CCCTATTACTCATCATGTTAAGG-3’ on Exon 3 and 
5’-TGGGCAGCTCTATGCAATGAAGG-3’ on Exon 4). Forward and reverse oligonucleotides for each 
were annealed and phosphorylated using T4 DNA Ligase Reaction Buffer and T4 Polynucleotide 
Kinase (New England Biolabs) at 37℃ for 30 min followed by 95℃ for 5 min. pX458 was digested 
using BbsI (Thermo Scientific, Yokohama, Japan) at 37℃ for 2 hrs, and gel purification was 
performed using a QIAquick Gel Extraction Kit (QIAGEN). The ligation reactions of pX458 and the 
annealed oligonucleotides were performed at room temperature for 4 hrs using a T4 DNA ligase Kit 
(New England Biolabs). Then, the ligated products were purified using PlasmidSafe exonuclease 
(Cambio) at 37℃ for 30 min. The plasmids were transformed into Stbl3, and amplified using Qiagen 
maxiprep kit. Each plasmid was transfected into A549 cells by electroporation using Amexa 
nucleofector II according to the manufacturer’s protocol. The transfectants were selected using 
puromycin prior to isolation of clones. Cell lines were tested for knockdown of RSK4 using Western 
blotting and the best clones selected for further experiments. 
 
Post-mortem tissue micro array 
The Royal Postgraduate Medical School archives were searched for metastatic lung cancer (LC) 
samples. The reports of 12,580 post-mortem (PM) examinations performed at the Hammersmith 
Hospital between January 1970 and December 2005 were reviewed. LC was identified in 499 cases. 
Patients who received anticancer therapy for their malignancy, as assessed through review of PM 
reports and medical notes, were excluded (n = 286). In total, formalin-fixed paraffin embedded 
(FFPE) tissue blocks pertaining to 213 patients were retrieved. These patients were further screened 
for stringent tissue quality criteria, including (1) confirmed histopathologic diagnosis of metastatic 
LC; (2) lack of significant autolytic degeneration of the target tissues; (3) complete PM dissection of 
all the organs; and (4) PM interval <24 h from death. 
Histotype classification as well as metastatic distribution was confirmed following review of newly 
cut Haematoxylin and Eosin (H&E) sections by a consultant pulmonary pathologist (FAM). The 
suitability of both primary and metastatic deposits to immunohistochemical (IHC) studies was 
confirmed following preliminary immunostaining for two pan-cytokeratin markers: MNF116 (Dako) 
incubated at 1:200 concentration for 1 h and CK Cam 5.2 (BD Biosciences) incubated at 1:20 
concentration for 1 h after 0.1% trypsin in phosphate buffered saline incubation for 10 min. PM 
specimens showing dubious or unsatisfactory MNF116/CK Cam 5.2 staining were discarded. Based 
on the combination of the above quality criteria, a total number of 98 cases were considered 
suitable to be included in the study. A tissue micro-array was constructed by obtaining three 1 mm 
cores from the most representative and better-preserved areas of the tumours and re-embedded in 
microarray blocks. 
This study protocol received full approval by an accredited Research Ethics Committee (Reference: 
06/Q0406/154). 
Survival analysis 
Univariate overall survival analysis for lung adenocarcinoma or lung squamous carcinoma patients 
was performed on microarray datasets using an online Kaplan-Meier plotter (kmplot.com) and 
patients stratified by their low or high expression status for the corresponding RSK isoform using the 
median as a cut-off expression value. Probes used for the analysis were as follow: RSK1; 203379_at, 
RSK2; 203843_at, RSK3; 212912_at and RSK4; 220737_at and 220738_s_at. 
 
Interrogation of public datasets for RSK expression 
Comparison of RSK isoform mRNA expression in cancer: lung and bladder cancer data were 
extracted from the The Cancer Genome Atlas (TCGA) pan-cancer dataset downloaded from the  
UCSC Xena Browser. Analysis was performed in R with plots created using the lattice package. 
Comparison of RSK isoforms mRNA expression between cancer and normal tissue: For lung, the 
same TCGA dataset as above was used. Analysis was performed in R and plots created using the 
lattice package. For bladder, the GEO RNA-Seq dataset GSE133624 was analysed in R and two 




Proteins were concentrated to 10 mg/mL only in the presence of AMP-PNP (Sigma-Aldrich), as 
previously reported for RSK2 NTKD (56). 1 μl RSK4 NTKD or RSK4 NTKD S232E was mixed with 1 μl of 
precipitant solution (20 % PEG 6000, 0.1 M TRIS pH8, 2 mM ZnCl2). 1 μl RSK4 NTKD pS232 was mixed 
with 1 μl of precipitant solution (18 % PEG 6000, 0.1 M TRIS pH8, 2 mM ZnCl2). Crystals were grown 
within 1 day at 18 °C by the sitting drop vapour diffusion method. 
 
Data collection and structure determination 
The crystals were flash-cooled in liquid nitrogen after a short soaking in cryo-protection solution 
(40% (w/v) glycerol, 20 % PEG 6000, 0.1 M TRIS pH8, 2 mM ZnCl2) and then frozen by plunging into 
liquid nitrogen. X-ray diffraction data were collected at Diamond Light Source beamlines I04-1, I03 
and I24 respectively for RSK4 NTKD, RSK4 NTKD pS232 and RSK4 NTKD S232E. Data were processed 
using XDS (57). The structures were determined by molecular replacement using the program 
PhaserMR (CCP4) (58) using respectively RSK2 NTKD structure (3G51) (56) for RSK4 NTKD and RSK4 
NTKD for RSK4 NTKD pS232 and S232E. The structures were refined using Refmac5 (59) and 
PHENIX.refine (60). PHENIX.Xtriage (60) found 1 pseudo-merohedral twin operator in RSK4 NTKD 
pS232 and S232E and a twin law h,-k,-l was applied during refinement with a PHENIX.refine. Once a 
satisfactory description of the protein electron density was complete, water molecules and AMP-
PNP were added using PHENIX.refine and PHENIX.LiganFit, respectively (60). Model building was 
performed using the graphics program Coot (61). Figures were prepared using PyMOL (DeLano 
Scientific). Coordinates have been deposited with the Protein Data Bank: RSK4 NTKD (6G77), RSK4 
NTKD pS232 (6G76) and RSK4 NTKD S232E (6G78). 
 
Docking 
Molecular docking simulations were performed with HADDOCK web docking software (62), using 
RSK4 NTKD structure and a phosphorylated peptide in random coil covering the sequence of the 
hydrophobic motif between residues 380 and 398 (NAHQLFKGF-pS-FVATSIAEE). AutoDock Vina (63) 
(64) was used for docking simulation of trovafloxacin sarafloxacin, tosufloxacin tosylate, 
ciprofloxacin and clinafloxacin on RSK4 NTKD structure using a docking box of 17×17×17 Å (grid-
point spacing of 1 Å). Optimal box size was estimated according to the radius of giration of 
trovafloxacin (65). Binding energy, electrostatic energy, the number of possible conformation(s) of 
the ligand–receptor complex and also predicted polar bonds were obtained from Vina.  
 
Trovafloxacin was prepared using the “LigPrep” (Schrödinger Release 2020-2: LigPrep, Schrödinger, 
LLC) module of Schrodinger before molecular docking. Specifically, the ligand was minimized using 
the OPLS3 force field, the possible ionization states were created at pH 7.0 ± 2.0, the tautomers 
were generated, specific chiralities of the ligands were retained, and a total of 12 conformations 
were generated relative to the indefinite chiralities. The docking box was generated using the 
“Receptor Grid Generation” (66) module of Schrodinger, and was placed in a comparable position as 
the AutoDock Vina box. All parameters were default. Trovafloxacin was docked into the allosteric 
surface of RSK4 NTKD using an extra precision (XP) algorithm of Glide (66). The pose with the best 
score was rescored using Prime (Schrödinger Release 2020-2: Prime, Schrödinger, LLC) MM-GBSA 
approach (67). The top-ranked pose was selected.  
 
 
Pymol (The PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC. http://ww.pymol.org)  




Differenctial scanning fluorimetry (DSF) 
DSF was performed using the fluorescent dye Sypro Orange (Sigma Aldrich) and a DNA Engine 
Opticon 2 (Bio-Rad) to monitor binding of Trovafloxacin and Ciprofloxacin to the RSK4 NTKD. The 
fluorescence intensity was plotted as a function of temperature and the curve’s inflection point (Tm) 





Far UV CD spectra were recorded on a Chirascan spectrometer (Applied Photophysics Ltd) equipped 
with a thermostated cell holder. Far UV measurements were performed at 20 °C in 15 mM NaCl 
using protein concentrations of 3.51, 5.08 and 6.37 μM respectively for RSK4 NTKD, RSK4 NTKD 
pS232 and RSK4 NTKD. The spectra were recorded in fused silica cuvettes of 1 mm path length. Five 
scans were averaged. Spectral decomposition for secondary structure predictions was achieved 
through DichroWeb (68) (69) using SELCON method. 
 
HDX-MS experiments 
Hydrogen/deuterium exchange reaction: Deuterium exchange reactions of Rsk4 (100 uM), and Rsk4 
(100 uM) with Trvoa (300 uM), were initiated by diluting the proteins in D2O (99.8% D2O ACROS, 
Sigma) in 25mM Tris-HCl pH8.0, 150 mM NaCl, 5mM TCEP and 4% DMSO to obtain a final D2O 
percentage of ∼92%. For all experiments, deuterium labelling was carried out at 23°C (unless 
otherwise stated) at five time points, 3 s on ice, 3 s, 30 s, 300 s, and 3,000 s in triplicate. The labelling 
reaction was quenched by the addition of chilled 2.4% (vol/vol) formic acid in 2 M guanidinium 
hydrochloride, to rapidly lower the pH.  Protein samples were then immediately snap frozen in liquid 
nitrogen and stored at −80°C prior to analysis. 
UPLC-HDX-MS: The quenched protein samples were rapidly thawed and subjected to proteolytic 
cleavage with pepsin followed by reversed phase HPLC separation. Briefly, the protein was passed 
through an Enzymate BEH immobilized pepsin column, 2.1 × 30 mm, 5 μm (Waters) at 200 μL/min 
for 2 min, the peptic peptides were trapped and desalted on a 2.1 × 5 mm C18 trap column (Acquity 
BEH C18 Van-guard pre-column, 1.7 μm, Waters). Trapped peptides were subsequently eluted over 
11 min using a 3%–43% gradient of acetonitrile in 0.1% v/v formic acid at 40 μL/min. Peptides were 
separated on a reverse phase column (Acquity UPLC BEH C18 column 1.7 μm, 100 mm x 1 mm 
(Waters, UK) and detected on a SYNAPT G2-Si HDMS mass spectrometer (Waters) over a m/z of 300 
to 2000, with the standard electrospray ionization (ESI) source with lock mass calibration using 
[Glu1]-fibrino peptide B (50 fmol/μL). The mass spectrometer was operated at a source temperature 
of 80°C and a spray voltage of 2.6 kV. Spectra were collected in positive ion mode. Peptide 
identification was performed by MSe (70) using an identical gradient of increasing acetonitrile in 
0.1% v/v formic acid over 11 min. 
Data analysis: The resulting MSe data were analyzed using Protein Lynx Global Server 3.0 software 
(Waters, UK) with an MS tolerance of 5 ppm. Mass analysis of the peptide centroids was performed 
using DynamX 3.0 software (Waters). Only peptides with a score > 6.4 were considered. The first 
round of analysis and identification was performed automatically by the DynamX 3.0 software, 
however, all peptides (deuterated and non-deuterated) were manually verified at every time point 
for the correct charge state, presence of overlapping peptides, and correct retention time. 
Deuterium incorporation was not corrected for back-exchange and represents relative, rather than 
absolute changes in deuterium levels. Changes in H/D amide exchange in any peptide may be due to 
a single amide or a number of amides within that peptide. The DynamX 3.0 software plots the 
standard deviation for every peptide. The error band shows the standard deviation of the plotted 
uptake or difference for each peptide. When there are multiple exposures, as in this experiment, for 
a given peptide, the maximum standard deviation is plotted for each peptide. A sigma multiplier of 1 
is applied to the standard deviation to produce the gray error bar plotted in Fig. 6I and fig. S12B. 
 
Auto-phosphorylation assay 
10 μM non-phosphorylated RSK4 NTKD was incubated at room temperature in 25 mM HEPES (pH 
7.5), 150 mM NaCl, 10 mM MgCl2, 5 mM DTT, 5% Glycerol, supplied with 2 mM ATP alone or in 
presence of 100 μM peptide covering the sequence of the hydrophobic motif between residues 380 
and 398 (HP: NAHQLFKGFSFVATSIAEE) (Alta Bioscience Ltd), or 100 μM of the phosphorylated 
peptide (pHP: NAHQLFKGF-pS-FVATSIAEE) (Alta Bioscience Ltd) for 30 min, 1 h and 2 h. Samples 
were immediately diluted with 2x Laemmli buffer, boiled for 5 min and analysed by 4-12% Bis-Tris 
SDS-PAGE gel and Western blotting using anti-Phospho-Rsk-1/2/3/4 (S221/227/S218/232) antibody 
(St John's Laboratory) and ECL (Millipore). 
 
Animal experiments 
All studies were performed under a UK Home office approved project license and in accordance with 
institutional welfare guidelines.  Mice were randomized by tumour burden. Analysis of Ct scan 
images to measure changes in tumour volume was done blinded. Animals were treated without 
knowledge of anticipated outcomes. No data points were removed as outliers. 
Xenograft experiments: For tumour growth experiments, 5x106 CRISPR-NT, CRISPR-RSK4 A549 or 
A549-Luc cells were injected subcutaneously into the flanks of female nu/nu-BALB/c mice. Tumour 
measurements were performed daily by caliper and volumes calculated using V=(length (mm)) x 
(width (mm)) x (width (mm)) x π/6. When tumours reached 50 mm3, treatment ± 3.5 mg/kg cisplatin 
in PBS (intraperitoneally weekly or twice weekly) and 30mg/kg trovafloxacin by daily oral gavage. 
For metastatic experiments, CRISPR-NT and CRISPR-RSK4 A549 cells (1x106 in 100 µl) were tail vein-
injected into SCID mice and tumours left to develop for 2 months. The animals were then sacrificed 
and their lungs extracted, fixed and embedded into paraffin. 10 microtome slices over a depth of 
600 µm were analysed microscopically for the presence of tumour nodules following H&E staining. 
 
KRASV12/TP53-/- (KP)-driven genetically engineered mouse model:  
For autochthonous tumour formation, lung tumours were initiated using intratracheal intubation of 
1x106 pfu (KrasLSL-G12D/+: Trp53flox/flox mice) adenovirus expressing Cre-recombinase (Gene 
Transfer Vector Core) in mice between 6-12 weeks of age. Mice were treated 14 weeks after adeno-
Cre infection with vehicle, trovafloxacin (175 mg/kg) 5 days per week by oral gavage, cisplatin (5 
mg/kg) weekly by i.p injection or combined trovafloxacin (175 mg/kg) 5 days per week by oral 
gavage and cisplatin (5 mg/kg) weekly by i.p injection for 3 weeks.  Tumour volume was measured by 
micro-CT analysis using the SkyScan 1176. Micro-CT data were processed and reconstructed using N-
Recon (SkyScan). Reconstructed data were subsequently imaged using DataViewer and tumour 
volumes were calculated using the CTan program (SkyScan).  Trovafloxacin was freshly prepared in 
sterile water before o.g. administration. Cisplatin was freshly solubilised in DMSO and diluted into 
PBS before i.p. administration. 
 
Tumour explant drug sensitivity assay 
Single drugs and combinations of cisplatin (25 µM) and trovafloxacin (40 µM) were tested on patient-
derived bladder tumour explants as in (71). 
 
 
Generation of SIGNIFICANT trial data 
Details of the design and analysis of the SIGNIFICANT trial is published elsewhere (31). In summary 
the trial randomised 1565 patients receiving cyclical chemotherapy for solid tumours or lymphoma 
between August 1999 and April 2003, who were at risk of temporary severe neutropenia (<500 
neutrophils per cubic millimetre) to receive either levofloxacin 500 mg once daily or placebo for 
seven days during the expected neutropenic period, for up to six chemotherapy cycles. The primary 
outcome was the incidence of clinically documented febrile episodes attributed to infection and 
overall survival time was not collected as part of the original design.  
Ethical approval was obtained for the conduct of the SIGNIFICANT Trial (West Midlands Multi-centre 
Research Ethics Committee (MREC) reference 99/7/08). Patients provided written informed consent 
at trial entry but this did not include permission for long term follow-up or documenting date of 
death. Subsequently, the original MREC advised that it was acceptable to trace date of death 
without further consent. Dates of death were obtained through the NHS Strategic Tracing Service 
(NSTS) who receive notification via the NHS central register when a death is registered and issue a 
formal notification. It advised that the vast majority of deaths in England and Wales are listed within 
6 weeks. Participants’ full name and date of birth were entered into the database and the patient 
was either confirmed as alive or date of death was displayed. Survival data from Scotland were 
obtained by sending patient information to the General Register Office for Scotland (GROS) which 
conducted patient tracing. The GROS advises that deaths are generally registered within 2 weeks. A 
small number of patients were traced through hospital records and matched using hospital number, 
date of birth and name. Initial patient tracing through NSTS was conducted between August 2007 
and January 2008, but in order to ensure at least five years follow-up at the time of tracing, this was 
repeated in late July 2008 where it was needed. Tracing was conducted through GROS during late 
May 2008.  
Survival time was calculated from trial entry until date of death from any cause. Any traced patients 
who had no date of death were assumed to be alive 6 weeks prior to tracing and a censored survival 
time was calculated using this endpoint. Patients alive at the time of tracing were censored at July 1st 
2007 for the first tracing set, June 1st 2008 for the second set and April 1st 2008 for patients in 
Scotland. For patients who could not be traced, date last known to be alive was taken from trial 
data; either date of last chemotherapy or date when came off study.  
 
Statistical analysis of the SIGNIFICANT trial 
The effect of treatment on overall survival time was investigated using Kaplan-Meier survival curves 
and Cox regression models. Univariable analysis included just treatment as a covariate within the 
model whilst multivariable analysis provided estimates of treatment effect adjusted for all relevant 
baseline prognostic factors that had been collected prospectively in the trial, specifically age (<40, 
40-59, 60+), World Health Organization (WHO) performance status (0-1, 2+), cancer type (breast, 
small cell lung cancer, germ cell, non-Hodgkin’s lymphoma, other) and chemotherapy setting 
(adjuvant, non-adjuvant). It was recognized that any effect of levofloxacin on survival might depend 
upon patients’ adherence to treatment. According to protocol, patients’ adherence was recorded at 
the end of each cycle by counting the number of returned tablets and patients were categorised 
prospectively as overall adherers or not on the basis of taking at least 80% of the trial medication (a 
similar approach taken in other studies). The survival analysis was carried out separately for 
adherers and non-adherers. The analysis included all randomised patients for whom adherence data 
was available. In addition, in order to evaluate the effect of treatment on long-term survival, 






Supplementary Figures  
 
 
Fig S1: Kinome siRNA screen hits in T24 cells and validation results. (A-C) Heat maps of siRNA 
targets modulating the response of T24 cells to cisplatin only (A), taxol only (B) or both drugs (C) 
based on the sensitivity index (SI) (as defined in (48)). SI>0.1 highlights sensitisation whereas SI<0.15 
highlights resistance. Results for four individual targeting oligonucleotides per gene are shown. (D) 
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Colour
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Cisplatin Paclitaxel
siRNA Oligo 1 Oligo 2 Oligo 3 Oligo 4 siRNA Oligo 1 Oligo 2 Oligo 3 Oligo 4
ACVRL1 NME1 ACVR1B PDK4
ADRBK1 PDGFRB AK3 PFKM
AK5 PIK3CB AKAP11 PHKB
AKT2 PIM1 AKAP5 PI4K2B
APEG1 PKIB AKIP PIK3CD
ARHGAP26 PKN1 ARK5 PINK1
ATR PRKACA CAMK2G PKN3
CALM1 PRKACB CDK7 PLAU
CAMK1D PRKAG3 CDKN2B PRKAR1B
CDC2 PRKCA CHKA PRKD1
CKMT2 PRKCZ CINP PRKD3
CSNK1A1 PRKD2 CSNK1D PRKX
CSNK2A2 PRKG1 CSNK1E RET
DGKH PRSS7 DGKB RIPK3
EIF2AK2 PTK7 DGUOK RIPK5
GALK1 SGK ERBB2 ROCK1
HIPK3 SKP2 ERK8 RPS6KC1
HUNK SMG1 ERN2 SH3KBP1
IBTK SORCS3 FASTK SNRK
LATS2 SRMS GIT1 STK17A
MAP2K4 SRPK1 GRK1 TK1
MAP2K6 STK25 HIPK2 TLK1
MAP3K5 STK38 HSPB8 TPK1
MAP3K9 STK4 LOC91807 TTBK1
MAPK1 TNK2 MAP2K7 XYLB
MAPK3 UHMK1 MAPK11
MAPK8 ULK3 MAPK4 IRAK2
MAPK8IP3 MELK ITK
MAPK9 AKAP8 NME6 ITPKA
MARCKS IRAK1 PACSIN1 ITPKB
MAST4 IRAK2 PANK1 MGC4796
MERTK ITK PANK4
MOS ITPK1
Colour Colour Colour Colour
SI > 0.3 0.2 to 0.3 0.15 to 0.2 0.1 to 0.15 SI < -0.4 -0.3 to -0.4 -0.2 to -0.3 -0.15 to -0.2 SI > 0.3 0.2 to 0.3 0.15 to 0.2 0.1 to 0.15 SI < -0.4 -0.3 to -0.4 -0.2 to -0.3 -0.15 to -0.2
Cisplatin Paclitaxel
 
Fig S2: RSK4 modulates chemo-resistance in NSCLC cells. (A) siRNA-mediated silencing of RSK4 
decreases cell survival to cisplatin (12.5 µM) and taxol (58 nM) in HOP62 and H1299 cells. NT; non-
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PARP normalised to vinculin expression from A549 cells treated with RSK4 or non-targeting (NT) 
siRNAs. (C) RSK4 overexpression in A549 renders them resistant to taxol. EV; empty-vector. (A-B) Cell 
number was determined by Crystal violet staining. Data shown are the mean ± SEM of 
quadruplicates. (D and G) Lysates from A549 cells transfected with or without a RSK4-encoding or EV 
plasmid for 48 h (D) or A549 CRISPR non-targeting (NT) or RSK4 knockout (#1, #2) clones (G) were 
analysed by SDS-PAGE/Western blotting for the indicated proteins (left panel) and optical 
densitometry was performed on three biological replicates (right panels). Detection of β-actin or 
vinculin (Vinc) was used as a loading control. (A-D) Data shown are representative of at least 
biological triplicates. (E) A549 RSK4-CRISPR cells were transfected with empty vector (EV) or RSK4-
coding cDNA and caspase 3/7 activity determined using a substrate-based assay. (F) Optical 
densitometry of Western blots for BCL2, cIAP1 and 2 normalised to vinculin expression from A549 
cells treated with RSK4 or non-targeting (NT) siRNAs. (H) RT-qPCR for cIAP1 and 2 from A549 cells 
transfected with or without a RSK4-encoding or EV plasmid for 48 h. (I) A549 NT and RSK4-CRISPR 
cells were transfected with EV or RSK4 cDNA and protein extracts were analysed by Western blotting 
for the indicated proteins 72h later. (J) A549 control or RSK4-CRISPR cells were transfected with a 
cIAP1 or cIAP2-encoding or EV plasmid for 24 h prior to treatment ± cisplatin for 48 h and caspase 
3/7 activity determination using a substrate-based assay. (C, E, F, G, H, I) Bar graphs represent mean 




Fig S3: RSK4 modulates the metastatic program in lung and bladder cancer cells. (A-B) RSK4 









































































































































































































































































length (A-right and B-bottom) of random-walk cell migration in lung (A549, EKVX and HOP62) and 
bladder (TCCSUP and J82) cancer cell lines. NT; non-targeting, EV; empty-vector. Red bar represent 
the median. (C) 36 microscopic fields of view for cells treated with non-targeting (NT) or RSK4-
targeting siRNAs such as those shown in Fig 2C were analysed in ImageJ to determine the Scattering 
Tree Factor or cellular Major Axis Length. Red bars represent mean ± SEM. (D and F) Optical 
densitometry of Western blots (n=3) for the indicated proteins normalised to vinculin expression 
from A549 cells transfected with RSK4 or non-targeting (NT) siRNAs (D) or empty-vector or RSK4-
encoding cDNA (F). (E) RSK4 silencing lead to a mesothelial-to-epithelial transition (MET) expression 
profile. Lysates from T24 cells treated for 72h with RSK4-targeting or NT siRNAs were analysed by 
SDS-PAGE/Western blotting for the indicated proteins. Detection of Vinculin was used as a loading 
control. E-Cadh; E-cadherin, N-Cadh; N-cadherin, Vim; vimentin, Vinc; vinculin. (F) Optical 
densitometry of Western blots (n=3) for changes in EMT markers following RSK4 or empty-vector 
(EV) overexpression in A549 cells. Normalisation to vinculin signal was used as a loading control. (G) 
Overexpression of RSK4 rescues the decreased motility of RSK4-CRISPR A549 cells. NT or RSK4-
CRISPR cells (#2) were transfected with either EV or RSK4 cDNA and random cell migration 
monitored using time-lapse microscopy for 18h. Left panel; Box-plot of cell speed. “n=”; number of 
cells tracked per condition. Right panel; individual cell tracks. (H) RSK4 or NT CRISPR A549 cells were 
transfected with a RelA-Firefly luciferase reporter construct and a Renilla luciferase control vector. 
The next day, lysates were analysed for Firefly luciferase activity normalised to that of the Renilla 
luciferase control using a luminescence plate reader. (A-D) Data shown are representative of three 
independent experiments with (A, B, G) performed in quadruplicates. (D and F) Bar graphs represent 




Fig S4: Active RELA overexpression rescues cell migration but not drug response changes 
downstream of RSK4 silencing. (A-B) Active RELA overexpression in RSK4-CRISPR (A) or wild-type 
A549 (B) corrects the changes in EMT markers (A) and the decrease in cell migration (B) observed 
following RSK4 downregulation. (A-lower panel) Optical densitometry quantification of n=3 repeats. 
CR#2; RSK4 CRISPR clone 2, Con; control, EV; empty vector.  (B) Cells were treated with non-
targeting (NT) or RSK4-targeting siRNAs and transfected 24 h later with either empty vector or active 
RELA cDNA. Time-lapse imaging was performed 24 h later for 18 h. Upper; Fold change in cell speed. 
Vinculin
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Bottom; cell tracks. Red bar; median. Stats; ANOVA with ***; p≤0.001, ns; not significant. (C-E) 
Active RELA overexpression in RSK4-CRISPR (C and E) or wild-type A549 (D) does not prevent drug 
sensitisation downstream of RSK4 downregulation. (D) Cells treated with NT or RSK4-targeting 
siRNAs for 24 h or (C and E) NT and RSK4-CRISPR cells were transfected with either empty-vector or 
active RELA cDNA. (C-D) 24 h later, cells were treated with or without cisplatin for 48 h and caspase 
3/7 activity determined using a substrate-based luminometric assay. (E) 72 h after vector 
transfection, cell lysates were analysed by Western blotting for the indicated proteins (upper panel) 
and repeats (n=3) were quantified by optical densitometry for changes in cIAP2 expression, 
normalised to those of vinculin used as a loading control (lower panel). Bar graphs represent mean ± 




Fig S5: RSK4 overexpression in lung cancer cells and clinical relevance. (A) A549 cells were 
transfected with RSK4 or non-targeting (NT) siRNAs for 48 h prior to centrifugation, fixation and 
paraffin embedding. Slices were stained for RSK4 expression and counterstained by DAB. Lower 
panel: corresponding representative RT-qPCR results. Data are average of 3 technical replicates ± SD. 
Probe 220737_at Probe 220738_s_at
D.
RSK1 (203379_at) RSK2 (203843_at) RSK3 (212912_at)
G.
































































































































(B) Lysates from A549 cells transfected or not (UT) for 48 h with non-targeting (NT) or RSK4 siRNAs 
or empty-vector or RSK4 cDNA were analysed by Western blotting to demonstrate the antibody’s 
specificity. Full blot is shown. Vinculin detection was used as a loading control. (C) Lysates from the 
indicated cell lines were analysed by SDS-PAGE/Western blotting for the indicated proteins with 
actin serving as a loading control. PIIG; type-II pneumocytes. (D) Kaplan–Meier analysis of overall 
survival for lung cancer patients (all subtypes) as a function of low or high RSK4 mRNA expression. 
Analysis was performed using the Km-plotter web interface (75) using two separate microarray 
probes. Median mRNA expression was used to determine the cut-off between low and high 
expressors. (E-F) The TCGA lung cancer datasets was analysed for respective expression of RSK 
isoforms in cancer samples (E) or for comparison of expression of RSK1-3 between normal lung (N) 
and lung adenocarcinoma (AdCa) samples (F). Stats: Student’s t-test. (G) Kaplan–Meier analysis of 
overall survival for lung adenocarcinoma patients as a function of low or high mRNA expression for 
RSK1, RSK2, and RSK3. Analysis was performed using the Km-plotter web interface (75) using the 
indicated microarray probes. Median mRNA expression was used to determine the cut-off between 






Fig S6: RSK4 is overexpressed in bladder cancer. (A) The bladder cancer TCGA dataset was analysed 
for the relative expression of RSK isoforms. Red bar; median. (B) Two microarray and one RNA-Seq 
(GSE133624) datasets were analysed for comparative expression of RSK4 between cancer (BC) and 
normal tissue. For the microarray datasets, the probes used to detect RSK4 mRNA are indicated. Red 
bar; median. Stats: Student’s t-test. 
 
 






















#1 30 0.064 
#2 60 0.25 #2 3 0.04 
#3 80 0.75 #3 1 0.016 
#4 30 0.066 #4 2 0.012 
#5 0 0 #5 40 0.134 




































































































































#7 60 0.09 #7 2 0.01 
#8 0 0 #8 2 0.037 
p = 0.017633368 
 
 
Fig S7: RSK4 downregulation prevents lung colonisation by A549 cells. 1.106 A459 NT or RSK4 
CRISPR cell clone #1 were injected through the tail vein of SCID mice. Animals were sacrificed 2 
months later and their lungs extracted, fixed and paraffin-embedded prior to 10 sections (each 
separated by 60µm) being H&E stained and the average lung involvement (%) and average diameter 
of lung tumour nodules determined.  
 
 
Fig S8: Rational for and identification of a RSK4 allosteric inhibitor. (A-C) RSK1 inhibition produces 

























































































































































































































































































































treated with or without DMSO or 50 µM of the pan-RSK inhibitor SL0101 prior to being overlaid with 
a collagen I matrix and 166 ng/ml EGF to provide chemo-attraction. Cell invasion was monitored 48h 
later by confocal microscopy following PFA-based fixation and Cytox Green staining. Box plot is 
representative of three independent experiment performed in quadruplicates with a total of 36 
fields of view acquired. Red bar represents the median. (B) Comparison of changes in sensitivity 
index to Cisplatin and Taxol obtained following silencing of RSK4 or RSK1 in lung (A549) or bladder 
(T24, TCCSUP and J82) cells lines. Cells were transfected with the indicated siRNAs or a non-targeting 
sequence and treated two days later with cisplatin (3.5 µM for bladder cells and 12.5 µM for A549 
cells) and taxol (40 nM for bladder cells and 58 nM for A549 cells) for 48h. Cell number was 
determined by Crystal violet staining and the sensitivity index calculated as in (48). Statistics: 
ANNOVA with n.s.; not significant, *; p<0.05, **; p<0.01, ***; p<0.001. (C) Left: Lysates for A549 cells 
treated with NT, RSK1 or 4 siRNAs were analysed by Western blotting for the indicated proteins. 
Vinculin detection was used as a loading control. Right: Optical densitometry of three biological 
replicate experiments normalised to vinculin and to the NT condition. (D) Dephosphorylated 
“inactive” RSK4 can be efficiently re-activated in vitro in the presence of recombinant active ERK2 as 
monitored using an HTRF® KinEASE™ platform. (E) Varying the concentration of ATP, ERK2 or RSK4 in 
the assay does not modify the inhibitory efficiency of moxifloxacin. (F) Dilution of pre-inhibited RSK4 
using IC50 for the indicated compounds rescues kinase activity, suggesting resversibility of the 
inhibition. BI-D; BI-D1870, Moxi; moxifloxacin. (G) HTRF-based RSK4 activation assays in the 
presence of the pan-RSK inhibitor, BI-D1870. Varying the concentration of ATP and ERK2, but not 
RSK4, modifies the inhibitory efficiency of BI-D1870. (H) Time-dependence assays for inhibition by 
moxifloxacin and BI-D1870 show linear relationship with product formation in the presence of both 
inhibitors. (I) Michaelis Menten kinetics for RSK4 in the presence of increasing concentrations of 
moxifloxacin show reduced Vmax (J) but maintenance of Km (K). (L) Moxifloxacin demonstrates 
higher potency against the dephosphorylated RSK4 (RSK4i) than activated RSK1 or 4. Moxifloxacine 
was incubated with dephosphorylated RSK4 (RSK4i), active/phosphorylated RSK4 (RSK4) or RSK1 and 
the enzymes subjected to HTRF assays in the presence of ERK2. (A-L) Results shown are 
representative of at least three independent repeats. (B-K) Data represent the mean of n=4 
replicates ± SEM. (A, B and E) Statistics: Student’s t-test with n.s.; not significant, *; p≤0.05, **; 




Fig S9: Not all floxacins inhibit RSK4 activation. (A) HTRF-based RSK4 activation assays in the 
absence or presence of increasing concentrations of the indicated representative floxacin 
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Fig S10: Floxacin compounds tested in our RSK4 activation assay, corresponding structures and pIC50 values. NA (Not Applicable) values points to 
compounds that failed to inhibit RSK4 activation at all tested concentrations. 
 
  
Compound pIC50 Structure Compound pIC50 Structure Compound pIC50 Structure Compound pIC50 Structure
Gemifloxacin <4 Balofloxacin 4.37 ± 0.20 Enrofloxacin NA Orbifloxacin NA
Trovafloxacin 5.59 ± 0.22 Gatifloxacin <4 Ciprofloxacin <4 Clinafloxacin NA
Piromidic Acid NA Marbofloxacin 5.07 ± 0.22 Perfloxacin <4
Tosufloxacin
tosylate
4.14 ± 0.23 Danofloxacin <4Moxifloxacin 5.20 ± 0.22
Difloxacin NAGatifloxacin <4




















































































































































Fig. S11: Floxacins inhibiting RSK4 reproduce cellular effects of RSK4 knockdown. (A) Floxacin 
compounds differ in their ability to sensitise A549 cells to cisplatin. Cells were treated with various 
Marbarfloxacin






























































































































































































































































































































150 16.5uM Trova (AB) Cis alone (B)
P(AB) Trova alone (A)
*
****










RSK4 NTKD (8 ? M)
Tm ( °C)
APO 31.61 ± 0.02


















T t  (oC)
concentrations of floxacins for 1 h prior to incubation with a dose range of cisplatin for 72 h before 
determining cell number by Alamar Blue staining. (B) Left: Isobologram for Cisplatin IC50 versus a 
concentration range for trovafloxacin demonstrates synergism between the two compounds in A549 
cell viability assays. Right: Synergism is separately confirmed by corresponding Bliss independence 
factors (P(AB)) calculation. Statistics 2-way ANOVA with *; p<0.05, **; p≤0.01,***; p<0.005, ****; 
p≤0.001. (C) Trovafloxacin shows increased ability over moxifloxacin in sensitising A549 cells to 
cisplatin and taxol. Cells were incubated with floxacin compounds for 1h prior to addition of taxol or 
cisplatin. Cell viability was determined 48h later using Alamar Blue. (D) Optical densitometry of 
Western blots (n=3) for cIAP1 and 2 of lysates from A549 cells treated with a dose range of 
trovafloxacin. Values are normalised to vinculin expression and to the untreated condition. (E-F) T24 
(E) and A549 (F) cells were subjected to (E) a random-walk cell migration assay for 18 h or (F) a 3D-
collagen invasion assay following treatment with or without trovafloxacin at the indicated 
concentrations. (E) N=80 cells were tracked per condition. Red bar; median. (F) Upper; 
representative confocal stacks with blue arrow representing bottom of plate. Lower; bar graph 
represent mean ± SEM of 9 stacks. (G) Cell lysates from A549 cells treated with/without 10 µM 
trovafloxacin for 24 h were analysed by Western blotting for the indicated proteins. Detection of 
vinculin was used as a loading control. Lower panel shows quantification of three biological 
replicates. (H) Differential Scanning Fluorimetry analysis of Ciprofloxacin (negative control) binding 
to RSK4 NTKD. Shown are the melting curves of dephosphorylated RSK4 NTKD (blue) and RSK4 NTKD 
in presence of 100 𝜇𝜇M Ciprofloxacin (red). Ciprofloxacin did not induce any notable temperature 
shifts indicating no binding to RSK4 NTKD. To maximise solubility, Ciprofloxacin was dissolved in HCl 
and the HCl final concentration in both RSK4 NTKD APO and Ciprofloxacin samples was 0.7 𝜇𝜇M. (A-G) 
Results shown are representative of at least three independent experiments. Statistics: ANOVA with 








Fig. S12: RSK4 structures and floxacin docking. (A) Far UV CD spectrum of RSK4 NTKD, RSK4 NTKD 
pS232 and RSK4 NTKD S232E reported in terms of mean residue ellipticity [θ]/(degree·cm−2·dmol−1). 
Deconvolution of the CD spectra of RSK4 NTKD, RSK4 NTKD pS232 and RSK4 NTKD S232E yield, 
respectively, the following percentages for secondary structure elements: 21.1% of α-helix, 31.6% of 
β-strands and 17.6% turns; 22.7% of α-helix, 29.3% of β-strands and 20.9% turns; 18.8% of α-helix, 
29.7% of β-strands and 20.8% turns. All the variations are within the uncertainty of the techniques 
and show no significant differences in the composition of secondary structural elements among the 
different proteins. (B) Cartoon representation of RSK4 NTKD pS232. βB-sheet is highlighted in red. In 
ball-and-stick are shown the phosphorylated S232 (pink) and R197, part of the HDR motif (blue). (C) 
Top panel: RSK1 NTKD active site bound to AMP-PCP (the AMP-PCP is in an orientation not 
favourable for γ-phosphate transfer). Middle panel: RSK2 NTKD active site bound to AMP-PNP and 














D 185, K 187 and N 200
AMP-PNP
DFG




D 198, K 200 and N 203
active site: the DFG motif, which positions ATP for phosphoryl transfer, is shown in brown; the 
substrate binding D, the catalytic K (indispensable for the formation of enzymatic intermediate 
during catalysis ) and the magnesium-binding N, located at the bottom of the active sites, are shown 
in purple; the K, which interacts with the β-phosphate of the ATP and help the correct positioning 
required for ATP binding and catalysis, is shown in black (part of the βB-sheet motif which is not 
visible in RSK1 structure). The relative position of the key residues reveals an almost identical 
arrangement between RSK1/2/4 NTKD active sites. All structures have been superimposed and are 
shown in the same orientation. (D) Kinase activity of RSK4 mutants. Hetero-phosphorylation of the 
HTRF biotinylated peptide S2 (1 μM) by 500 nM of wild-type or indicated mutant versions of RSK4 
NTKD in the presence of 10 mM MgCl2 and 2 mM ATP. The time points follow a classic Michaelis-
Menten trend, showing that our recombinant RSK4 proteins are fully functional in vitro, independent 
of PDK1 activity. DSF and HTRF experiments were run using the same buffer used to crystallise the 
RSK4 NTKD, RSK4 NTKD pS232 and RSK4 NTKD S232E. (E-F) Docking Controls. Cartoon representation 
of RSK4 bound to Trovafloxacin and two positive and negative controls. All structures are in the 
same orientation and were superimposed using the RSK4 NTKD structure. The βB-sheet is 









Fig. S13: Identifying mutations that perturb the communication between the active site and 
allosteric site through exhaustive computational alanisation. (A) An exhaustive computational 
alanine scanning of RSK4 is carried out by removing the weak interactions of each residue, one at a 
time. This computational alanine scanning identifies mutations that perturb strongly the 















































transient time t1/2. The alanisation of the highlighted residues (red, Z score > 1.64, corresponding to 
p < 0.05) induces the strongest reduction in the communication between the allosteric and active 
sites. (B) The active-site ligand (green sticks), the ligand Trova (yellow sticks) and the allosteric 
residues where TROVA binds (spheres) are shown on the structure of RSK4. Residues highly 
important under alanisation (high Z score in (A)) are shown as sticks and form two pathways, which 
connect the active site and allosteric site. (C) The top-ranked pose of Trovafloxacin, Tosufloxacin 
Tosylate and Sarafloxacin (positive controls) obtained using Autodock VINA are shown in marine 
blue, pink and purple respectively. (D) The top-ranked pose of Trovafloxacin, Ciprofloxacin and 
Clinafloxacin (negative controls) are shown in marine blue, pale-brown and brown respectively. (E) 
Docking of Trovafloxacin to the RSK4 NTKD structure. The top-ranked pose of Trovafloxacin obtained 
using Autodock VINA and GLIDE are shown in marine blue and hot-pink respectively. The Structure 
were superimposed using the RSK4 NTKD structure and oriented as in figure 6E. The βB-sheet is 
highlighted in red and the activation loop in pink. Key residues of the binding site are shown in ball-
and-stick coloured by element. H-bonds are identical in the two structures and are shown as blue 
and pink dotted lines respectively for the Autodock VINA and GLIDE outputs. (F) The difference in 
Markov transient times between the random walks originating at the AMP-PNP and Trovafloxacin-
bound allosteric sites (Δt1/2 = t1/2 ANP – t1/2 TROVA) is computed for all residues of the protein. As 
shown by the positive values of Δt1/2 > 0 , the binding of trovafloxacin leads to increased 
communication with the residues of the active site (relative to AMP-PNP), whereas AMP-PNP 
exhibits increased communication with residues in the activation loop and lower lobe of RSK4 
(relative to trovafloxacin), as indicated by Δt1/2 < 0. The value of Δt1/2 for each residue is mapped 
onto the protein structure (bottom). The active site and upper lobe are identified as regions better 
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 Y A  M  K V L K K A S L K V R D R V R T K  M  E R D  I  L V E V N  H P F  I  V K L H Y A F Q T E G K L Y L  I  L D F L R G G D V F T R L S K E V L F T E E D V K F Y L A E L A L A L D H L H  Q L G  I  V Y R D L K P E N I  L L D E  I G H 
 335  340  345  350  355  360  365  370  375  380  385  390  395  400  405  410  415  420  425  430  435  440 
 I  K L T D F G L S K E S V D Q E K K A Y S F C G T V E Y  M  A P E V V N R R G H S Q S A D  W  W  S Y G V L M  F E M  L T G T L P F Q  G K D R N E T  M  N  M I  L K A K L G  M  P Q F L S A E A Q S L L R  M  L F K R N P A N R L G S E G V 
 445  450  455  460  465  470  475  480  485  490  495  500  505  510  515  520  525  530  535  540  545  550 
 E E  I  K R H L F F A N I D  W  D K L Y K R E V Q P P F K P A S G K P D D T F C F D P E F T A K T P K D S P G L P A S A N  A H  Q L F K G F S F V A T S  I A E E Y K  I  T P  I  T S A N V L P  I  V Q I N  G N  A A Q F G E V Y E L K E D 
 555  560  565  570  575  580  585  590  595  600  605  610  615  620  625  630  635  640  645  650  655  660 
 I G V G S Y S V C K R C  I H  A T T N  M  E F A V K  I  I D K S K R D P S E E  I  E  I  L M  R Y G Q  H P N I  I  T L K D V F D D G R Y V Y L V T D L M  K G G E L L D R  I  L K Q K C F S E R E A S D  I  L Y V  I  S K T V D Y L H  C Q  G V V H 
 665  670  675  680  685  690  695  700  705  710  715  720  725  730  735  740  745  750  755  760  765  770 
 R D L K P S N I  L Y  M  D E S A S A D S  I  R  I C D F G F A K Q L R G E N  G L L L T P C Y T A N F V A P E V L M  Q  Q  G Y D A A C D  I W  S L G V L F Y T  M  L A G Y T P F A N  G P N  D T P E E  I  L L R  I G N  G K F S L S G G N  W  D N 
 775  780  785  790  795  800  805  810  815  820  825  830  835  840  845  850  855  860  865  870  875  880 
 I  S D G A K D L L S H  M  L H  M  D P H  Q R Y T A E Q I  L K H S W I  T H R D Q L P N  D Q P K R N  D V S H V V K G A  M  V A T Y S A L T H K T F Q P V L E P V A A S S L A Q R R S M  K K R T S T G L 
 885  890  895  900  905  910  915  920  925  930  935  940  945  950  955  960  965  970 




















































kinase 1 AGC kinase c-terminal kinase 2
Fig. S14: Deuterium exchange mass-spectrometry. (A) Peptic peptide coverage of RSK4. (B) 
Butterfly plot displayed in the DynamX 3.0 software (Waters, UK) showing the incorporation of 
deuterium at successive time points indicated by the different colours as above.  Relative fractional 
uptake is shown on the y-axis, without correction for back-exchange, while the experimental error is 





Fig. S15: The hydrophobic motif of RSK4 modulates the activity of the RSK4-NTKD. 10 μM RSK4 
NTKD was incubated with 2 mM ATP alone or in presence of 100 μM of unphosphorylated (HP) or 
phosphorylated (pHP) hydrophobic motif peptide. Aliquots were collected after 30 minutes, 1 hour 
and 2 and phosphorylation of Ser 232 assessed by Western blotting. SDS-PAGE gels stained with 
Coomassie blue are shown on the top panel as loading control. On the left panels 10 μM RSK4 NTKD 
pS232, RSK4 NTKD, RSK4 NTKD S232A were used respectively as positive control, time zero, and 
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Patient 1 Patient 2 Patient 3 Patient 4
- + - +- + - + - + - +- + - +Cis
- - + +- - + + - - + +- - + +Trova




































Patient #1 #2 #3 #4
Cisplatin + Trova 1 0.8 0.45 0.95
Bliss factor 1 0.36 0.2 0.94
Fig. S16: Trovafloxacin potentiates the effects of cisplatin treatment on tumours in vivo in mice 
and ex vivo on patient tumour explants. (A) Differences in tumour sizes corresponding to xenograft 
experiment presented in Fig 7A. Statistics: ANOVA with *; p<0.05, **; p<0.005, ****; p≤0.001. (B) 
Exemplar of caspase 3 cleavage staining (brown signal) obtained on FFPE A549 tumour samples from 
experiments presented as Fig 7A-B. Scale bar: 30 µm. (C) Optical densitometry of Western blotting 
(n=3) for cIAP2 and cleaved caspase 3 from lysates of KP cells treated with a dose range of 
trovafloxacin. Signal was normalised to that for vinculin (loading control) and that of untreated 
condition. (D) Lung CT scans 3D reconstruction of vehicle-only and combination-treated KP mice. 
Exemplars animated 3D reconstructions of lung micro-CT scans for vehicle-only and 
trovafloxacin/cisplatin combination-treated KRASV12/TP53-/- (KP)-driven genetically-engineered 
mouse model from experiments shown as Fig 7D-F. Individual tractable tumours are alternatively 
coloured. Corresponding supplementary animation movies are provided (movies S1-S2). (E) Bladder 
cancer explants from 4 patients were treated with/without cisplatin (40 µM) and trovafloxacin (25 
µM) alone or in combination and viability determined 5 days later as previously described (71). Left-
hand table provides comparison between experimentally observed decrease in survival fraction  in 













































Fig. S18: Levofloxacin added to cisplatin-based chemotherapy improves survival in patients with 
cancers including lung and bladder. (A) Levofloxacin inhibits RSK4 activation by ERK2 in our HTRF 
assay. Data are representative of three replicate experiments and show mean ± SEM of 
quadruplicates. (B) Lysates from A549 cells treated with or without levofloxacin (Levo) for 24 h were 
analysed by SDS-PAGE/Western blotting for the indicated proteins. Detection of vinculin was used as 
a loading control. (C) Kaplan-Meier overall survival curves of the SIGNIFICANT Trial comparing 
patients who were adherent (left panel) or non-adherent (right panel) in taking either levofloxacin 
(solid line) or placebo (dashed line) during chemotherapy for several cancer types including lung and 
bladder cancer. Hazard ratios (HR) are shown for univariate and multivariable analyses. (D) Forest 












Table S1: Summary of data collection, structure determination, and refinement statistics for the 





Table S2: siRNA sequences used to target RSK4 
Gene Name siRNA sequence (5’-3’) Provider 
RPS6KA6 D_01 GCAAATGTATTACCAATTG – Exon 14 
Dharmacon RPS6KA6 D_02 GGACAACATCCCAACATTA – Exon 16 RPS6KA6 D_03 GGTGGAAACTGGGACAATA – Exon 20 





Table S3: RT-qPCR primers usedGene Primers sequence (5’-3’) 
RPS6KA6 Fwd: TGCTCAAGGTTCTTGGTCAG (Exon 3) Rev: TTTGTCCGAACTCTGTCTCG (Exon 5) 
HPRT Fwd: TGACCTTGATTTATTTTGCATACC (Exon 2 
Rev: CGAGCAAGACGTTCAGTCCT (Exon 3) 
Bcl-2 Fwd:  TTTGAGTTCGGTGGGGTCAT (Exon 1) Rev: TGACTTCACTTG TGGCCCAG (Exon 2) 
PDCD4 Fwd: GCAGAAAATGCTGGGACTGAG (Exon 4) Rev: TGTACCCCAGACACCTTTGC (Exon 5) 
cIAP1 Fwd: AGCTAGTCTGGGATCCACCTC Rev: GGGGTTAGTCCTCGATGAAG 
cIAP2 Fwd: TGGAAGCTACCTCTCAGCCTAC Rev: GGAACTTCTCATCAAGGCAGA 
 
 
Protein Species MW (kDa) Company Cat. No. Clone 
RSK4 Rabbit 84 Abcam Ab76117 EP1982Y 
cIAP1 Rabbit 72 Abcam Ab108361 EPR4673 
cIAP2 Rabbit 72 Cell Signalling 3130 58C7 
BCL2 Mouse 25 Santa Cruz Sc-509 100 
E-Cadherin Rabbit 135 Cell Signalling 3195 - 
N-Cadherin Mouse 135 Cell Signalling 14215 13A9 
Vimentin Rabbit 57 Cell Signalling 5741 D21H3 
PARP Rabbit 29 Cell Signalling 9542 - 
Caspase 3 (Cleaved; Asp175) Rabbit 17,19 Cell Signalling 9661 - 
Caspase 7 Rabbit 20,35 Cell Signalling 9492 - 
NFkB 1 p105/P50 Rabbit 105, 50 Cell Signalling 12540 - 
NFkB p65  Mouse 65 Cell Signalling 6956 L8F6 
FLAG Mouse  Sigma F1804 M2 
Vinculin Mouse 150 Sigma V9131 hVIN-1 
Tubulin Mouse 52 Sigma T5168 B-5-1-2 
Actin Mouse 42 Sigma A2228 AC-74 
Lamin B Goat 70 Santa Cruz sc-6216 C-20 
P300 Mouse 300 Santa Cruz sc-48343 F-4 
Phospho Ser 89 -P300 Rabbit 300 Santa Cruz sc-130210 - 
HSP90 Mouse 90 Sigma 05-594 - 
 
  
The following data files are available in the online version of the supplement: 
 
Data file S1. Trovafloxacin has no major activity against a panel of 140 recombinant kinases. 
(Excel) 
Movie S1. Micro-CT projection of lung of an exemplar vehicle-only treated KP mouse 
Movie S2.  Micro-CT projection of lung of an exemplar trovafloxacin/cisplatin combination treated 
KP mouse 
 
 
 
 
 
 
 
